Pardes Biosciences (PRDS) S-1 21 Jan 22 IPO registration Financial data

Cover Page

Cover Page	9 Months Ended
	Sep. 30, 2021
Cover [Abstract]
Entity Registrant Name	PARDES BIOSCIENCES, INC.
Document Type	S-1
Amendment Flag	false
Entity Central Index Key	0001822711
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)		Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents		$ 26,384,000	$ 3,410,000
Prepaid expenses and other current assets		676,000	194,000
Total current assets		27,060,000	3,604,000
Other assets		1,521,000
Total Assets		28,581,000	3,604,000
Current liabilities:
Accounts payable		2,747,000	1,394,000
Accrued expenses		3,224,000	408,000
Simple agreements for future equity (SAFE)			14,808,000
Total current liabilities		5,971,000	16,610,000
Total liabilities		5,971,000	16,610,000
Commitments and Contingencies
Convertible preferred stock, $0.00001 par value; no shares authorized at December 31, 2020 and 13,923,367 shares authorized at September 30, 2021 (unaudited); no shares issued and outstanding at December 31, 2020 and 13,923,356 shares issued and outstanding at September 30, 2021 (unaudited); liquidation preference of $0 and $51,615 at December 31, 2020 and September 30, 2021 (unaudited), respectively		59,132,000
Stockholders' Equity (Deficit):
Common stock value
Additional paid-in capital		655,000
Accumulated deficit		(37,177,000)	(13,006,000)
Total stockholders' equity (deficit)		(36,522,000)	(13,006,000)
Total Liabilities, Class A Common Stock Subject to Possible Redemption and Stockholders' Equity (Deficit)		28,581,000	3,604,000
FS DEVELOPMENT CORP. II
Current assets:
Cash and cash equivalents		48,330	8,800
Prepaid expenses		522,202	0
Total current assets		570,532	8,800
Deferred offering cost		0	82,900
Investments held in Trust Account		201,262,186	0
Total Assets		201,832,718	91,700
Current liabilities:
Accounts payable		183,911	1,032
Accrued expenses		2,164,500	16,700
Franchise tax payable		149,091	0
Note payable		0	50,000
Total current liabilities		2,497,502	67,732
Deferred underwriting commissions		7,043,750	0
Total liabilities		9,541,252	67,732
Commitments and Contingencies
Class A common stock subject to possible redemption, $0.0001 par value; 20,125,000 and -0- shares at $10.00 per share as of September 30, 2021 and December 31, 2020, respectively		201,250,000	0
Stockholders' Equity (Deficit):
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding
Common stock value		60
Class B common stock, $0.0001 par value; 10,000,000 shares authorized; 2,875,000 shares issued and outstanding	[1]		288
Class B common stock, $0.0001 par value; 10,000,000 shares authorized; 5,031,250 shares issued and outstanding as of September 30, 2021 and December 31, 2020		503	503
Additional paid-in capital			24,497
Additional paid in capital			24,712
Accumulated deficit		(8,959,097)	(1,032)
Total stockholders' equity (deficit)		(8,958,534)	23,968
Total Liabilities, Class A Common Stock Subject to Possible Redemption and Stockholders' Equity (Deficit)		$ 201,832,718	$ 91,700
[1]	This number includes up to 375,000 shares of Class B common stock subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters.

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Common stock, par value (in Dollars per share)	$ 0.00001	$ 0.00001
Common stock, shares authorized	25,187,755	10,000,000
Common stock, shares issued	6,935,000	6,859,000
Common stock, shares outstanding	2,380,715	0
Temporary equity shares authorized	13,923,367
Temporary equity shares issued	13,923,356
Temporary equity shares outstanding	13,923,356
Temporary Equity, Liquidation Preference	$ 51,615
Redeemable Convertible Preferred Stock [Member]
Temporary equity, par value (in Dollars per share)	$ 0.00001	$ 0.00001
Temporary equity shares authorized	13,923,367	0
Temporary equity shares issued	13,923,356	0
Temporary equity shares outstanding	13,923,356	0
Temporary Equity, Liquidation Preference	$ 51,615	$ 0
FS DEVELOPMENT CORP. II
Shares subject to possible redemption	20,125,000
Preferred stock par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, shares authorized		10,000,000
Class A Common Stock | FS DEVELOPMENT CORP. II
Temporary equity, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Shares subject to possible redemption	20,125,000	0
subject to possible redemption per share (in Dollars per share)	$ 10	$ 10
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	602,500	0
Common stock, shares outstanding	602,500	0
Class B Common Stock | FS DEVELOPMENT CORP. II
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	10,000,000	10,000,000
Common stock, shares issued	5,031,250	5,031,250
Common stock, shares outstanding	5,031,250	5,031,250
Common stock, shares issued		2,875,000
Common stock, shares outstanding		2,875,000
Common shares subject to forfeiture		375,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)		1 Months Ended	3 Months Ended	4 Months Ended	7 Months Ended	9 Months Ended	10 Months Ended
		Sep. 30, 2020	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Sep. 30, 2021	Dec. 31, 2020
Operating expenses:
Research and development					$ 2,197,000	$ 17,792,000	$ 4,563,000
General and administrative expenses					583,000	6,389,000	750,000
Total operating expenses					2,780,000	24,181,000	5,313,000
Loss from operations					(2,780,000)	(24,181,000)	(5,313,000)
Interest income						10,000
Change in fair value of SAFE liability					(885,000)		(7,693,000)
Total other expense					(885,000)	10,000	(7,693,000)
Net loss					$ (3,665,000)	$ (24,171,000)	$ (13,006,000)
Weighted average shares outstanding, basic and diluted (in Shares)						1,463,172
Basic and diluted net loss per share (in Dollars per share)						$ (16.52)
FS DEVELOPMENT CORP. II
General and administrative expenses - related party			$ 30,000			$ 80,000
Franchise tax expense			50,411			149,723
Operating expenses:
General and administrative expenses		1,032	1,142,579	$ 1,032		3,334,485
Loss from operations		(1,032)	(1,222,990)			(3,564,208)
Interest income			5,073			12,186
Net loss		$ (1,032)	$ (1,217,917)	$ (1,032)		$ (3,552,022)
Weighted average shares outstanding, basic and diluted (in Shares)	[1]			2,500,000
Basic and diluted net loss per share (in Dollars per share)				$ 0
Class A Common Stock | FS DEVELOPMENT CORP. II
Operating expenses:
Weighted average shares outstanding, basic and diluted (in Shares)			20,727,500			17,083,104
Basic and diluted net loss per share (in Dollars per share)			$ (0.05)			$ (0.16)
Class B Common Stock | FS DEVELOPMENT CORP. II
Operating expenses:
Weighted average shares outstanding, basic and diluted (in Shares)		4,375,000	5,031,250			4,915,865
Basic and diluted net loss per share (in Dollars per share)		$ 0	$ (0.05)			$ (0.16)
[1]	This number excludes an aggregate of up to 375,000 shares of Class B common stock subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters.

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Parentheticals)	4 Months Ended
	Dec. 31, 2020shares
FS DEVELOPMENT CORP. II | Class B Common Stock
Shares of Class B common stock subject to forfeiture	375,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)		Total	FS DEVELOPMENT CORP. II	Common Stock	Additional Paid-In Capital	Additional Paid-In CapitalFS DEVELOPMENT CORP. II	Accumulated Deficit	Accumulated DeficitFS DEVELOPMENT CORP. II	Class A Common StockFS DEVELOPMENT CORP. II	Class B Common StockFS DEVELOPMENT CORP. II	Class B Common StockCommon StockFS DEVELOPMENT CORP. II	Redeemable Convertible Preferred StockPreferred Stock
Beginning Balance at Feb. 26, 2020
Beginning Balance (in Shares) at Feb. 26, 2020
Net loss		$ (3,665,000)					$ (3,665,000)
Ending Balance at Sep. 30, 2020		(3,665,000)	$ 23,968			$ 24,497	(3,665,000)	$ (1,032)		$ 503
Ending Balance (in Shares) at Sep. 30, 2020										5,031,250
Beginning Balance at Feb. 26, 2020
Beginning Balance (in Shares) at Feb. 26, 2020
Net loss		$ (13,006,000)					(13,006,000)
Net loss		(13,006,000)
Ending Balance at Dec. 31, 2020		(13,006,000)	23,968		$ 24,712	24,497	(13,006,000)	(1,032)		$ 503	$ 288
Ending Balance (in Shares) at Dec. 31, 2020										5,031,250	2,875,000
Beginning Balance at Aug. 20, 2020			25,000			24,497				$ 503
Beginning Balance (in Shares) at Aug. 20, 2020										5,031,250
Net loss			(1,032)					(1,032)
Net loss			(1,032)
Ending Balance at Sep. 30, 2020		(3,665,000)	23,968			24,497	(3,665,000)	(1,032)		$ 503
Ending Balance (in Shares) at Sep. 30, 2020										5,031,250
Beginning Balance at Aug. 20, 2020			25,000			24,497				$ 503
Beginning Balance (in Shares) at Aug. 20, 2020										5,031,250
Issuance of Series A convertible preferred stock and Class B common stock to Sponsor	[1]		25,000			24,712				$ 288
Issuance of Series A convertible preferred stock and Class B common stock to Sponsor (in Shares)	[1]									2,875,000
Net loss			(1,032)					(1,032)
Net loss			(1,032)
Ending Balance at Dec. 31, 2020		(13,006,000)	23,968		24,712	24,497	(13,006,000)	(1,032)		$ 503	$ 288
Ending Balance (in Shares) at Dec. 31, 2020										5,031,250	2,875,000
Sale of Private Placement Shares			6,025,000			6,024,940			$ 60
Sale of Private Placement Shares (in Shares)									602,500
Accretion of Class A common stock subject to possible redemption amount			(11,455,480)			(6,049,437)		(5,406,043)
Net loss			(168,193)					(168,193)
Ending Balance at Mar. 31, 2021			(5,574,705)					(5,575,268)	$ 60	$ 503
Ending Balance (in Shares) at Mar. 31, 2021									602,500	5,031,250
Beginning Balance at Dec. 31, 2020		(13,006,000)	23,968		24,712	24,497	(13,006,000)	(1,032)		$ 503	$ 288
Beginning Balance (in Shares) at Dec. 31, 2020										5,031,250	2,875,000
Ending Balance at Jun. 30, 2021			(7,740,617)					(7,741,180)	$ 60	$ 503
Ending Balance (in Shares) at Jun. 30, 2021									602,500	5,031,250
Beginning Balance at Dec. 31, 2020		$ (13,006,000)	23,968		24,712	$ 24,497	(13,006,000)	(1,032)		$ 503	$ 288
Beginning Balance (in Shares) at Dec. 31, 2020										5,031,250	2,875,000
Issuance of Series A convertible preferred stock and Class B common stock to Sponsor												$ 44,324,000
Issuance of Series A convertible preferred stock and Class B common stock to Sponsor (in Shares)												9,771,414
Conversion of SAFE agreements into shares of convertible preferred stock												$ 14,808,000
Conversion of SAFE agreements into shares of convertible preferred stock (in Shares)		14,808										4,151,942
Vesting of restricted common stock (in Shares)				2,379,715
Exercise of common stock options (in Shares)				1,000
Exercise of common stock options		$ 5,000			5,000
Stock-based compensation		650,000			650,000
Net loss		(24,171,000)	(3,552,022)				(24,171,000)
Ending Balance at Sep. 30, 2021		(36,522,000)	(8,958,534)		655,000		(37,177,000)	(8,959,097)	$ 60	$ 503		$ 59,132,000
Ending Balance (in Shares) at Sep. 30, 2021				2,380,715					602,500	5,031,250		13,923,356
Beginning Balance at Mar. 31, 2021			(5,574,705)					(5,575,268)	$ 60	$ 503
Beginning Balance (in Shares) at Mar. 31, 2021									602,500	5,031,250
Net loss			(2,165,912)					(2,165,912)
Ending Balance at Jun. 30, 2021			(7,740,617)					(7,741,180)	$ 60	$ 503
Ending Balance (in Shares) at Jun. 30, 2021									602,500	5,031,250
Net loss			(1,217,917)					(1,217,917)
Net loss			(1,217,917)
Ending Balance at Sep. 30, 2021		$ (36,522,000)	$ (8,958,534)		$ 655,000		$ (37,177,000)	$ (8,959,097)	$ 60	$ 503		$ 59,132,000
Ending Balance (in Shares) at Sep. 30, 2021				2,380,715					602,500	5,031,250		13,923,356
[1]	This number includes up to 375,000 shares of Class B common stock subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters.

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Parentheticals)	9 Months Ended
	Sep. 30, 2021USD ($)
Payments of Stock Issuance Costs	$ 176,000
Series A Convertible Preferred Stock
Payments of Stock Issuance Costs	$ 176,000

Condensed Consolidated Statem_5

Condensed Consolidated Statement of Cash Flows - USD ($)	1 Months Ended	4 Months Ended	7 Months Ended	9 Months Ended	10 Months Ended
	Sep. 30, 2020	Dec. 31, 2020	Sep. 30, 2020	Sep. 30, 2021	Dec. 31, 2020
Cash Flows from Operating Activities:
Net loss			$ (3,665,000)	$ (24,171,000)	$ (13,006,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation				650,000
Change in fair value of SAFE liability			885,000		7,693,000
Changes in operating assets and liabilities:
Prepaid expenses and other current assets			(41,000)	(482,000)	(44,000)
Accounts payable			852,000	1,119,000	1,394,000
Accrued expenses			413,000	2,747,000	408,000
Net cash used in operating activities			(1,556,000)	(20,137,000)	(3,555,000)
Cash Flows from Financing Activities:
Payment of deferred offering costs				(176,000)
Proceeds from Issuance of Convertible Preferred Stock				44,500,000	44,500,000
Proceeds from issuance of SAFE agreements			5,005,000		6,965,000
Proceeds from exercise of common stock options				5,000
Cash paid for deferred offering costs				(1,218,000)
Net cash provided by financing activities			5,005,000	43,111,000	6,965,000
Net change in cash			3,449,000	22,974,000	3,410,000
Cash - beginning of the period				3,410,000
Cash - end of the period	$ 3,449,000	$ 3,410,000	3,449,000	$ 26,384,000	3,410,000
Supplemental schedule of non-cash financing activity:
Other receivable in connection with the issuance of SAFE agreements					150,000
Conversion of SAFE agreements into shares of convertible preferred stock				14,808
Deferred offering costs included in accounts payable and accrued expenses				$ 302,000
FS DEVELOPMENT CORP. II
Cash Flows from Operating Activities:
Net loss	(1,032)	(1,032)		(3,552,022)
Adjustments to reconcile net loss to net cash used in operating activities:
Income earned from investments held in Trust Account				(12,186)
Changes in operating assets and liabilities:
Prepaid expenses				(522,202)
Franchise tax payable				149,091
Accounts payable	9,032	1,032		57,879
Accrued expenses				2,119,500
Net cash used in operating activities	8,000	0		(1,759,940)
Cash Flows from Investing Activities
Cash deposited in Trust Account				(201,250,000)
Net cash used in investing activities				(201,250,000)
Cash Flows from Financing Activities:
Proceeds from note payable to related party	50,000	50,000		150,000
Payment of deferred offering costs		(41,200)
Repayment of note payable to related party				(200,000)
Proceeds received from initial public offering, gross				201,250,000
Proceeds received from private placement				6,025,000
Offering costs paid	(41,200)			(4,175,530)
Net cash provided by financing activities	8,800	8,800		203,049,470
Net change in cash	16,800	8,800		39,530
Cash - beginning of the period				8,800
Cash - end of the period	16,800	8,800	$ 16,800	48,330	$ 8,800
Supplemental disclosure of noncash activities:
Offering costs included in accounts payable				125,000
Offering costs included in accrued expenses	4,830			28,300
Deferred underwriting commissions in connection with the initial public offering				$ 7,043,750
Deferred offering costs paid by Sponsor in exchange for issuance of Class B common stock	$ 25,000	25,000
Deferred offering costs included in accrued expenses		$ 16,700

Description of Organization and

Description of Organization and Business Operations	4 Months Ended	9 Months Ended
	Dec. 31, 2020	Sep. 30, 2021
Description of Organization and Business Operations		1. Organization and Basis of Presentation Description of Business Pardes Biosciences, Inc. (Pardes or the Company) was incorporated in the state of Delaware on February 27, 2020 and is located in Carlsbad, California. The Company is a clinical-stage biopharmaceutical company developing novel therapeutic compounds to treat and prevent diseases with high unmet medical need, where our chemistry platform can provide differentiated tools to develop potential therapies against specific molecular targets. By leveraging our deep understanding of reversible covalent chemistry, biology, and drug development, we have built a structure-based discovery platform with specific strengths in targeting reactive nucleophiles — such as those in cysteine proteases — to discover and develop novel product candidates. Our lead program seeks to create an oral drug which could be used to treat or prevent all coronavirus associated diseases, from COVID-19 Basis of Presentation These financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP). The Company’s date of inception was February 27, 2020 and the fiscal year-end Liquidity and Going Concern As of September 30, 2021, the Company has devoted substantially all of its efforts to organizing and staffing, business planning, raising capital, identifying and acquiring its product candidates and conducting preclinical studies, and has not realized revenues from its planned principal operations. In addition, the Company has a limited operating history, has incurred operating losses since inception and expects that it will continue to incur net losses into the foreseeable future as it continues the development of its product candidates. As of December 31, 2020 and September 30, 2021 (unaudited), the Company had an accumulated deficit of $13.0 million and $37.2 million, respectively. The Company believes its cash and cash equivalents of $3.4 million as of December 31, 2020, together with the gross proceeds of $44.5 million received from the issuance of shares of the Company’s Series A convertible preferred stock in January 2021 (see Note 5), anticipated net losses and the uncertainties surrounding its ability to raise additional capital as needed, as discussed below, raise substantial doubt about its ability to continue as a going concern for a period of one year following the date that the financial statements for the period February 27, 2020 (inception) through December 31, 2020 and the nine months ended September 30, 2021 are issued. As a result, the Company will be required to raise additional capital and plans to finance its cash needs through public or private equity or debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. As further described in Note 10, on June 29, 2021 the Company executed a definitive business combination agreement, as amended on November 7, 2021, between it and FS Development Corp. II. If the merger is unable to be completed and the Company is not able to secure adequate additional funding, it may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or delay or reduce the scope of its planned development programs. Any of these actions could materially harm the Company’s business, results of operations and future prospects. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The accompanying financial statements do not reflect any adjustments relating to the recoverability and reclassifications of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. Other Risks and Uncertainties The Company is subject to a number of risks similar to other early-stage biopharmaceutical companies, including, but not limited to, changes in any of the following areas that the Company believes could have a material adverse effect on its future financial position or results of operations: risks related to the successful discovery and development of its product candidates, ability to raise additional capital, development of new technological innovations by its competitors and delay or inability to obtain chemical or biological intermediates from such suppliers required for the Company’s product candidates, including due to the impact of the current COVID-19 The current COVID-19 COVID-19
FS DEVELOPMENT CORP. II[Member]
Description of Organization and Business Operations	Note 1 — Description of Organization, Business Operations and Basis of Presentation FS Development Corp. II (the “Company”) is a blank check company incorporated in Delaware on August 21, 2020. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies. As of December 31, 2020, the Company had not commenced any operations. All activity for the period from August 21, 2020 (inception) through December 31, 2020 relates to the Company’s formation and the proposed initial public offering described below. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating The Company’s sponsor is FS Development Holdings II, LLC, a Delaware limited liability company (the “Sponsor”). The Company’s ability to commence operations is contingent upon obtaining adequate financial resources through a proposed public offering (the “Proposed Public Offering”) of 10,000,000 shares of Class A common stock (each, a “Public Share” and collectively, the “Public Shares”) at $10.00 per share (or 11,500,000 shares if the underwriters’ over-allotment option is exercised in full), which is discussed in Note 3, and the sale of 400,000 shares of Class A common stock (or 430,000 shares if the underwriters’ over-allotment option is exercised in full) (each, a “Private Placement Share” and collectively, the “Private Placement Shares”), at a price of $10.00 per Private Placement Share in a private placement to the Sponsor that will close simultaneously with the Proposed Public Offering. The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Proposed Public Offering and the sale of Private Placement Shares, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (as defined below) (excluding the deferred underwriting commissions and taxes payable on the interest earned on the Trust Account) at the time of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act 1940, as amended (the “Investment Company Act”). Upon the closing of the Proposed Public Offering, management has agreed that an amount equal to at least $10.00 per share sold in the Proposed Public Offering, including proceeds from the sale of the Private Placement Shares to the Sponsor, will be held in a trust account (“Trust Account”) located in the United States at JP Morgan Chase Bank, N.A. with Continental Stock Transfer & Trust Company acting as trustee, and invested only in U.S. “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 The Company will provide the holders (the “Public Stockholders”) of the Company’s outstanding Public Shares with the opportunity to redeem all or a portion of their Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then held in the Trust Account (initially anticipated to be $10.00 per Public Share). The per-share The Certificate of Incorporation will provide that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 20% of the Public Shares, without the prior consent of the Company. The Sponsor and the Company’s officers and directors (the “Initial Stockholders”) have agreed not to propose an amendment to the Certificate of Incorporation to modify the substance or timing of the Company’s obligation to redeem 100% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or with respect to any other material provisions relating to stockholders’ rights or pre-initial If the Company is unable to complete a Business Combination within 24 months from the closing of the Proposed Public Offering or during any extended period of time that the Company may have to consummate a Business Combination as a result of an amendment to the Certificate of Incorporation (the “Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the board of directors, liquidate and dissolve, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.​​​​​​​ The Initial Stockholders have agreed to waive their rights to liquidating distributions from the Trust Account with respect to the Founder Shares and Private Placement Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Stockholders acquire Public Shares in or after the Proposed Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriters have agreed to waive their rights to the deferred underwriting commission (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be only $10.00. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party (except for the Company’s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a letter of intent, confidentiality or other similar agreement or business combination agreement (a “Target”), reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per Public Share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or Target that executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of the Proposed Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”). The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers, prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. Basis of Presentation The accompanying financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. The Company does not have sufficient liquidity to meet its anticipated obligations over the next year from the issuance of these financial statements. In connection with the Company’s assessment of going concern considerations in accordance with FASB’s Accounting Standards Update (“ASU”) 2014-15, Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging	Note 1 — Description of Organization and Business Operations FS Development Corp. II (the “Company”) is a blank check company incorporated in Delaware on August 21, 2020. The Company was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses (the “Business Combination”). The Company is an emerging growth company and, as such, the Company is subject to all of the risks associated with emerging growth companies. As of September 30, 2021, the Company had not commenced any operations. All activity for the period from August 21, 2020 (inception) through September 30, 2021 relates to the Company’s formation and the initial public offering (the “Initial Public Offering”) described below, and, subsequent to the Initial Public Offering, identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company will generate non-operating The Company’s sponsor is FS Development Holdings II, LLC, a Delaware limited liability company (the “Sponsor”). The registration statements for the Company’s Initial Public Offering became effective on February 16, 2021. On February 19, 2021, the Company consummated its Initial Public Offering of 20,125,000 shares of Class A common stock, par value $0.0001 per share (“Class A Common Stock”) including the issuance of 2,625,000 shares of Class A Common Stock as a result of the underwriter’s exercise in full of its over-allotment option, (each, a “Public Share” and collectively, the “Public Shares”) at $10.00 per share, generating gross proceeds of approximately $201.3 million, and incurring offering costs of approximately $11.5 million, of which approximately $7.0 million was for deferred underwriting commissions (see Note 5). Simultaneously with the closing of the Initial Public Offering, the Company consummated the private placement (the “Private Placement”) of 602,500 shares of Class A Common Stock (each, a “Private Placement Share” and collectively, the “Private Placement Shares”), at a price of $10.00 per Private Placement Share to the Sponsor, generating proceeds of approximately $6.0 million (see Note 4). Upon the closing of the Initial Public Offering and the Private Placement, approximately $201.3 million ($10.00 per share of Class A Common Stock) of the net proceeds of the sale of the Public Shares in the Initial Public Offering and of the Private Placement Shares in the Private Placement were placed in a trust account (“Trust Account”) located in the United States, with Continental Stock Transfer & Trust Company acting as trustee, and are invested only in U.S. “government securities” within the meaning of Section 2(a)(16) of the Investment Company Act having a maturity of 185 days or less or in money market funds meeting certain conditions under Rule 2a-7 The Company’s management has broad discretion with respect to the specific application of the net proceeds of the Initial Public Offering and the sale of Private Placement Shares, although substantially all of the net proceeds are intended to be applied generally toward consummating a Business Combination. There is no assurance that the Company will be able to complete a Business Combination successfully. The Company must complete one or more initial Business Combinations having an aggregate fair market value of at least 80% of the net assets held in the Trust Account (excluding the deferred underwriting commissions and taxes payable on the interest earned on the Trust Account) at the time of the agreement to enter into the initial Business Combination. However, the Company will only complete a Business Combination if the post-transaction company owns or acquires 50% or more of the voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment Company Act”). The Company will provide the holders (the “Public Stockholders”) of the Public Shares upon the completion of a Business Combination either (i) in connection with a stockholder meeting called to approve the Business Combination or (ii) by means of a tender offer. The decision as to whether the Company will seek stockholder approval of a Business Combination or conduct a tender offer will be made by the Company, solely in its discretion. The Public Stockholders will be entitled to redeem their Public Shares for a pro rata portion of the amount then held in the Trust Account (initially anticipated to be $10.00 per Public Share). The per-share The Certificate of Incorporation provides that a Public Stockholder, together with any affiliate of such stockholder or any other person with whom such stockholder is acting in concert or as a “group” (as defined under Section 13 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)), will be restricted from redeeming its shares with respect to more than an aggregate of 20% of the Public Shares, without the prior consent of the Company. The Sponsor and the Company’s officers and directors (the “Initial Stockholders”) agreed not to propose an amendment to the Certificate of Incorporation to modify the substance or timing of the Company’s obligation to redeem 100% of the Public Shares if the Company does not complete a Business Combination within the Combination Period (as defined below) or with respect to any other material provisions relating to stockholders’ rights or pre-initial If the Company is unable to complete a Business Combination within 24 months from the closing of the Initial Public Offering, or February 19, 2023, or during any extended period of time that the Company may have to​​​​​​​ consummate a Business Combination as a result of an amendment to the Certificate of Incorporation (the “Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share The Initial Stockholders agreed to waive their rights to liquidating distributions from the Trust Account with respect to the Founder Shares and Private Placement Shares if the Company fails to complete a Business Combination within the Combination Period. However, if the Initial Stockholders acquire Public Shares in or after the Initial Public Offering, they will be entitled to liquidating distributions from the Trust Account with respect to such Public Shares if the Company fails to complete a Business Combination within the Combination Period. The underwriter has agreed to waive its rights to the deferred underwriting commission (see Note 5) held in the Trust Account in the event the Company does not complete a Business Combination within the Combination Period and, in such event, such amounts will be included with the other funds held in the Trust Account that will be available to fund the redemption of the Public Shares. In the event of such distribution, it is possible that the per share value of the residual assets remaining available for distribution (including Trust Account assets) will be only $10.00. In order to protect the amounts held in the Trust Account, the Sponsor agreed to be liable to the Company if and to the extent any claims by a third party (except for the Company’s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a letter of intent, confidentiality or other similar agreement or business combination agreement (a “Target”), reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per Public Share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or Target that executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriter of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”)​​​​​​​. The Company will seek to reduce the possibility that the Sponsor will have to indemnify the Trust Account due to claims of creditors by endeavoring to have all vendors, service providers, prospective target businesses or other entities with which the Company does business, execute agreements with the Company waiving any right, title, interest or claim of any kind in or to monies held in the Trust Account. Proposed Business Combination and Related Transaction On June 29, 2021, the Company entered into an agreement and plan of merger (the “Merger Agreement”) by and among the Company, Orchard Merger Sub, Inc., a Delaware corporation, a wholly-owned subsidiary of the Company (“Merger Sub”), Pardes Biosciences, Inc., a Delaware corporation (“Pardes”) and Shareholder Representative Services LLC, solely in its capacity as the representative, agent and attorney-in-fact merge with and into Pardes, with Pardes surviving as a wholly-owned subsidiary of the Company (the “Merger”). Upon the closing of the Merger (the “Closing”), it is anticipated that the Company will change its name to “Pardes Biosciences, Inc.” and is referred to herein as “New Pardes” as of the time following such change of name. The date on which the Closing actually occurs is hereinafter referred to as the “Closing Date.” Consideration and Structure Under the Merger Agreement, the Company has agreed to acquire all of the outstanding equity interests of Pardes in exchange for 32,500,000 shares of Class A Common Stock, to be paid at the effective time of the Merger. Pursuant to the Merger Agreement, at or prior to the effective time of the Merger, each option exercisable for Pardes equity that is outstanding immediately prior to the effective time of the Merger shall be assumed by the Company and continue in full force and effect on the same terms and conditions as are currently applicable to such options, subject to adjustments to exercise price and number of shares of Class A Common Stock issued upon exercise. Representations, Warranties and Covenants The parties to the Merger Agreement have agreed to customary representations and warranties for transactions of this type. The representations and warranties of Pardes made under the Merger Agreement will not survive the Closing. In addition, the parties to the Merger Agreement agreed to be bound by certain customary covenants for transactions of this type, including, among others, covenants with respect to the conduct of Pardes, the Company and their respective subsidiaries during the period between execution of the Merger Agreement and the Closing. The covenants made under the Merger Agreement will not survive the Closing. Each of the parties to the Merger Agreement has agreed to use its reasonable best efforts to cause all actions and things necessary to consummate and expeditiously implement the Merger. Conditions to Closing Under the Merger Agreement, the obligations of the parties to consummate the Merger are subject to the satisfaction or waiver of certain customary closing conditions of the respective parties, including, without limitation: (i) the approval and adoption of the Merger Agreement and transactions contemplated thereby by requisite vote of the Company’s stockholders (the “Company Stockholder Approval”) and Pardes’ stockholders (the “Pardes Stockholder Approval”); (ii) the receipt of consents or approvals from the applicable governmental, regulatory or administrative authorities; (iii) the aggregate cash proceeds from Company’s trust account, together with the proceeds from the Subscriptions (as defined below), equaling no less than $100,000,000 (after deducting any amounts paid to Company stockholders that exercise their redemption rights in connection with the Merger and net of the Company’s unpaid liabilities), (iv) (A) the representations and warranties of the Company, Pardes and Merger Sub contained in the Merger Agreement (other than each party’s respective Fundamental Representations, as defined in the Merger Agreement) being true and correct as of the date of the Merger Agreement and as of the Closing Date, except for any failure to be true and correct that would not have or reasonably be expected to have a Material Adverse Effect (as defined in the Merger Agreement) and (B) each party’s respective Fundamental Representations being true and correct as of the date of the Merger Agreement and as of the Closing Date, except for de minimis inaccuracies; (v) the absence of a Material Adverse Effect since the date of the Merger Agreement; (vi) the Company has not redeemed the Class A Common Stock of the Company in an amount that would cause the Company to have net tangible assets of less than $5,000,001; and (vii) the Company’s initial listing application with Nasdaq in connection with the Merger has been conditionally​​​​​​​ approved and, immediately following the effective time of the Merger, the Company has satisfied any applicable initial and continuing listing requirements of Nasdaq, and the Company has not received any notice of non-compliance Liquidity and Capital Resources As of September 30, 2021, the Company had approximately $48,000 in cash, and working capital deficit of approximately $1.8 million (not taking into account approximately $149,000 of tax obligations that may be paid using investment income classified in the Trust Account). The Company’s liquidity needs prior to the consummation of the Initial Public Offering were satisfied through the payment of $25,000 from the Sponsor to cover certain offering costs on behalf of the Company in exchange for issuance of Founder Shares (as defined in Note 4), and loan proceeds from the Sponsor of approximately $200,000 under the Note (see Note 4). The Company repaid the Note in full on February 19, 2021. Subsequent to the consummation of the Initial Public Offering, the Company’s liquidity has been satisfied through the net proceeds from the consummation of the Initial Public Offering and the Private Placement held outside of the Trust Account. In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, provide the Company Working Capital Loans (as defined in Note 4). As of September 30, 2021, there were no amounts outstanding under any Working Capital Loans. Based on the foregoing, management believes that the Company will have sufficient working capital and borrowing capacity from the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors to meet its needs through the earlier of the consummation of a Business Combination or one year from this filing. Over this time period, the Company will be using the funds held outside of the Trust Account for paying existing accounts payable, identifying and evaluating prospective initial Business Combination candidates, performing due diligence on prospective target businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating the Business Combination.

Basis of Presentation and Summa

Basis of Presentation and Summary of Significant Accounting Policies	4 Months Ended	9 Months Ended
	Dec. 31, 2020	Sep. 30, 2021
Basis of Presentation and Summary of Significant Accounting Policies		2. Summary of Significant Accounting Policies Unaudited Interim Financial Information The accompanying interim balance sheet as of September 30, 2021, and the statements of operations and comprehensive loss, statements of convertible preferred stock and stockholders’ deficit and cash flows for the period February 27, 2020 (inception) through September 30, 2020 and for the nine months ended September 30, 2021 are unaudited. In management’s opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of September 30, 2021 and the results of its operations and its cash flows for the period February 27, 2020 (inception) through September 30, 2020 and for the nine months ended September 30, 2021 in accordance with U.S. GAAP. The financial data and other information disclosed in these notes related to the period February 27, 2020 (inception) through September 30, 2020 and for the nine months ended September 30, 2021 are also unaudited. The results for the Company during the interim periods are not necessarily indicative of the results expected for the full fiscal year or any other interim period. Use of Estimates The preparation of the Company’s financial statements requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Such estimates include the valuation of the Simple Agreements for Future Equity (SAFE) agreements, the valuation of stock-based awards and accrual of research and development expenses. Management evaluates its estimates on an ongoing basis. Although estimates are based on the Company’s historical experience, knowledge of current events, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions. Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Concentration of Credit Risk Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash and money market accounts. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held. Comprehensive Loss Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner Deferred Offering Costs The Company capitalizes costs that are directly associated with in-process in-process Fair Value of Financial Instruments The carrying amounts of cash and cash equivalents, prepaid expenses and other current assets, accounts payable, and accrued expenses are considered to be representative of their respective fair values because of the short-term nature of those instruments. Prior to their conversion, the Company remeasured its SAFE agreements to fair value each reporting period (see Note 3). Accrued Research and Development Expense The Company is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants, and contract research organizations, in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company reflects research and development expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the preclinical study as measured by the timing of various aspects of the study or related activities. The Company determines accrual estimates through review of the underlying contracts along with discussions with research and other key personnel as to the progress of studies, or other services being conducted. During the course of a study, the Company adjusts its rate of expense recognition if actual results differ from its estimates. Research and Development Expenses Research and development expenses are charged to expense as incurred. Research and development expenses primarily consist of costs incurred for services provided by outside organizations and consultants for preclinical and clinical activities, salaries and related expenses for personnel performing research and development activities, and supplies used in research and development activities. Patent Costs Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain. Stock-Based Compensation Stock-based compensation expense represents the grant date fair value of employee and non-employee For restricted stock awards, the fair value of the award is the estimated fair value of the Company’s common stock on the grant date. The fair value of the shares of common stock has historically been determined by the Company’s board of directors as there was no public market for the common stock. The board of directors determines the fair value of the common stock by obtaining third-party valuations of the Company’s common stock using the option pricing method and the probability-weighted expected return method. Significant assumptions used in determining the fair value of common stock include volatility, discount for lack of marketability, and the expected timing of a future liquidity event. Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning As of December 31, 2020 and for all periods presented, the Company maintained a valuation allowance against its deferred tax assets as the Company concluded it had not met the “more likely than not” to be realized threshold. Changes in the valuation allowance when they are recognized in the provision for income taxes may result in a change in the estimated annual effective tax rate. The Company records uncertain tax positions on the basis of a two-step more-likely-than-not ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax lia Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The chief operating decision maker is the chief executive officer. The Company views its operations and manages its business as one operating segment and one reportable segment. No product revenue has been generated since inception and all assets are held in the United States. Net Loss Per Share Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. There were no common shares outstanding as of December 31, 2020 and September 30, 2020 (unaudited). Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares and dilutive common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. For the period presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares): February 27, February 27, Nine (unaudited) Conversion of outstanding convertible preferred stock — — 13,923,356 Outstanding stock options — — 1,604,933 Restricted common stock subject to repurchase or forfeiture 6,859,000 6,261,500 4,554,285 Total 6,859,000 6,261,500 20,082,574
FS DEVELOPMENT CORP. II[Member]
Basis of Presentation and Summary of Significant Accounting Policies	Note 2 — Summary of Significant Accounting Policies Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of December 31, 2020. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage limit of $250,000. At December 31, 2020, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under FASB ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheet primarily due to their short-term nature. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Deferred Offering Costs Associated with the Proposed Public Offering Deferred offering costs consist of legal fees incurred through the balance sheet date that are directly related to the Proposed Public Offering and that will be charged to stockholder’s equity upon the completion of the Proposed Public Offering. Should the Proposed Public Offering prove to be unsuccessful, these deferred costs, as well as additional expenses to be incurred, will be charged to operations. Net Loss Per Common Share The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” Net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period, excluding common stock subject to forfeiture. Weighted average shares at December 31, 2020 were reduced for the effect of an aggregate of 375,000 shares of Class B common stock that are subject to forfeiture by the Sponsor if the over-allotment option is not exercised in full or in part by the underwriters (see Note 6). At December 31, 2020, the Company did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into shares of common stock and then share in the earnings of the Company. As a result, diluted loss per common share is the same as basic loss per common share for the period presented. Income Taxes The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. Deferred tax assets were deemed immaterial as of December 31, 2020. FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of December 31, 2020. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. The provision for income taxes was deemed to be de minimis for the period from August 21, 2020 (inception) through December 31, 2020. Recent Accounting Pronouncements The Company’s management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.	Note 2 — Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation The accompanying unaudited condensed consolidated financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the three and nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected through December 31, 2021 or any future periods. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Form 8-K Restatement of Previously Reported Financial Statements In preparation of the Company’s unaudited condensed consolidated financial statements for the quarterly period ended September 30, 2021, the Company concluded it should restate its previously issued financial statements to classify all Public Shares in temporary equity. In accordance with the SEC and its staff’s guidance on redeemable equity instruments in ASC 480-10-S99, In accordance with SEC Staff Accounting Bulletin No. 99, “Materiality,” and SEC Staff Accounting Bulletin No. 108, “Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements,” the Company evaluated the corrections and has determined that the related impact was material to the previously filed financial statements that contained the error, reported in the Company’s Form 8-K “Post-IPO Form 10-Qs The impact of the restatement to the Post-IPO paid-in As of February 19, 2021 As Previously Adjustment As Restated Total assets $ 203,119,261 $ 203,119,261 Total liabilities $ 7,351,899 $ 7,351,899 Class A common stock subject to possible redemption 190,767,360 10,482,640 201,250,000 Preferred stock — — — Class A common stock 165 (105 ) 60 Class B common stock 503 — 503 Additional paid-in 5,051,492 (5,051,492 ) — Accumulated deficit (52,158 ) (5,430,983 ) (5,483,201 ) Total stockholders’ equity (deficit) $ 5,000,002 $ (10,482,640 ) $ (5,482,638 ) Total Liabilities, Class A Common Stock Subject to Possible Redemption and Stockholders’ Equity (Deficit) $ 203,119,261 $ — $ 203,119,261 The impact of the restatement on the financial statements for the Affected Quarterly Periods is presented below. The table below presents the effect of the financial statement adjustments related to the restatement discussed above of the Company’s previously reported balance sheet as of March 31, 2021: As of March 31, 2021 As Previously Adjustment As Restated Total assets $ 202,959,356 $ 202,959,356 Total liabilities $ 7,284,061 $ 7,284,061 Class A common stock subject to possible redemption 190,675,290 10,574,710 201,250,000 Preferred stock — — — Class A common stock 166 (106 ) 60 Class B common stock 503 — 503 Additional paid-in 5,168,561 (5,168,561 ) — Accumulated deficit (169,225 ) (5,405,983 ) (5,575,268 ) Total stockholders’ equity (deficit) $ 5,000,005 $ (10,574,710 ) $ (5,574,705 ) Total Liabilities, Class A Common Stock Subject to Possible Redemption and Stockholders’ Equity (Deficit) $ 202,959,356 $ — $ 202,959,356 The Company’s statement of stockholders’ equity has been restated to reflect the changes to the impacted stockholders’ equity accounts described above. The table below presents the effect of the financial statement adjustments related to the restatement discussed above of the Company’s previously reported statement of cash flows for the three months ended March 31, 2021: Three Months Ended March 31, 2021 As Previously Adjustment As Restated Supplemental Disclosure of Noncash Financing Activities: Initial value of Class A common stock subject to possible redemption $ 190,767,360 $ (190,767,360 ) $ — Change in value of Class A common stock subject to possible redemption $ (92,070 ) $ 92,070 $ — The table below presents the effect of the financial statement adjustments related to the restatement discussed above of the Company’s previously reported balance sheet as of June 30, 2021: As of June 30, 2021 As Previously Adjustment As Restated Total assets $ 202,246,887 $ 202,246,887 Total liabilities $ 8,737,504 $ 8,737,504 Class A common stock subject to possible redemption 188,509,380 12,740,620 201,250,000 Preferred stock — — — Class A common stock 188 (128 ) 60 Class B common stock 503 — 503 Additional paid-in 7,334,449 (7,334,449 ) — Accumulated deficit (2,335,137 ) (5,405,983 ) (7,741,180 ) Total stockholders’ equity (deficit) $ 5,000,003 $ (12,740,620 ) $ (7,740,617 ) Total Liabilities, Class A Common Stock Subject to Possible Redemption and Stockholders’ Equity (Deficit) $ 202,246,887 $ — $ 202,246,887 The Company’s statement of stockholders’ equity has been restated to reflect the changes to the impacted stockholders’ equity accounts described above. The table below presents the effect of the financial statement adjustments related to the restatement discussed above of the Company’s previously reported statement of cash flows for the six months ended June 30, 2021: Six Months Ended June 30, 2021 As Previously Adjustment As Restated Supplemental Disclosure of Noncash Financing Activities: Initial value of Class A common stock subject to possible redemption $ 190,767,360 $ (190,767,360 ) $ — Change in value of Class A common stock subject to possible redemption $ (2,257,980 ) $ 2,257,980 $ — The impact to the reported amounts of weighted average shares outstanding and basic and diluted earnings per share is presented below for the Affected Quarterly Periods: Earnings Per Share As Previously Adjustment As Restated Three Months Ended March 31, 2021 Net loss $ (168,193 ) $ — $ (168,193 ) Weighted average shares outstanding – Class A common stock 20,727,500 (11,054,667 ) 9,672,833 Basic and diluted earnings per share – Class A common stock $ — $ (0.01 ) $ (0.01 ) Weighted average shares outstanding – Class B common stock 4,681,250 4,681,250 Basic and diluted earnings per share – Class B common stock $ (0.04 ) $ 0.03 $ (0.01 ) Earnings Per Share As Previously Adjustment As Restated Three Months Ended June 30, 2021 Net loss $ (2,165,912 ) $ — $ (2,165,912 ) Weighted average shares outstanding – Class A common stock 20,125,000 602,500 20,727,500 Basic and diluted earnings per share – Class A common stock $ — $ (0.08 ) $ (0.08 ) Weighted average shares outstanding – Class B common stock 5,633,750 5,031,250 Basic and diluted earnings per share – Class B common stock $ (0.38 ) $ 0.30 $ (0.08 ) Earnings Per Share As Previously Adjustment As Restated Six Months Ended June 30, 2021 Net loss $ (2,334,105 ) $ — $ (2,334,105 ) Weighted average shares outstanding – Class A common stock 20,125,000 (4,894,296 ) 15,230,704 Basic and diluted earnings per share – Class A common stock $ — $ (0.12 ) $ (0.12 ) Weighted average shares outstanding – Class B common stock 5,299,938 4,857,217 Basic and diluted earnings per share – Class B common stock $ (0.44 ) $ 0.32 $ (0.12 ) Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging revised standard. This may make comparison of the Company’s unaudited condensed consolidated financial statements with another public company that is neither an emerging growth company nor an emerging growth company that has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.​​​​​​​ Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates. Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of September 30, 2021 and December 31, 2020. Investments Held in the Trust Account The Company’s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in income on investments held in the Trust Account in the accompanying unaudited condensed consolidated statement of operations. The estimated fair values of investments held in the Trust Account are determined using available market information. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. As of September 30, 2021 and December 31, 2020, the Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts. Fair Value Measurements Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: • Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; • Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and • Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement. Offering Costs Associated with the Initial Public Offering Offering costs consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering that were charged to stockholders’ equity upon the completion of the Initial Public Offering. The Company classifies deferred underwriting commissions as non-current Class A Common Stock Subject to Possible Redemption The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Class A common stock subject to mandatory redemption (if any) is classified as liability instruments and are measured at fair value. Conditionally redeemable Class A common stock (including Class A common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, Class A common stock is classified as stockholders’ equity. As part of the Private Placement, the Company issued 602,500 shares of Class A common stock to the Sponsor (“Private Placement Shares”). These Private Placement Shares will not be transferable, assignable or salable until 30 days after the completion of our initial business combination, as such are considered non-redeemable Effective with the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount, which resulted in charges against additional paid-in Income Taxes The Company follows the asset and liability method of accounting for income taxes under FASB ASC Topic 740, “Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. As of September 30, 2021, and December 31, 2020, the Company had deferred tax assets with a full valuation allowance against them. FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of September 30, 2021 or December 31, 2020. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of September 30, 2021 and December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. Net Income (Loss) Per Share of Common Stock The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” The Company has two classes of shares, which are referred to as Class A common stock and Class B common stock. Income and losses are shared pro rata between the two classes of shares. Net income (loss) per common share is calculated by dividing the net income (loss) by the weighted average shares of common stock outstanding for the respective period. Accretion associated with the redeemable Class A common stock is excluded from earnings per share as the redemption value approximates fair value. The following table reflects presents a reconciliation of the numerator and denominator used to compute basic and diluted net income (loss) per share for each class of common stock: For the Three Months Ended For the Nine Months Ended Class A Class B Class A Class B Basic and diluted net loss per ordinary share: Numerator: Allocation of net loss $ (980,031 ) $ (237,886 ) $ (2,758,291 ) $ (793,731 ) Denominator: Basic and diluted weighted average ordinary shares outstanding 20,727,500 5,031,250 17,083,104 4,915,865 Basic and diluted net loss per ordinary share $ (0.05 ) $ (0.05 ) $ (0.16 ) $ (0.16 ) For the Period From Class A Class B Basic and diluted net loss per ordinary share: Numerator: Allocation of net loss $ — $ (1,032 ) Denominator: Basic and diluted weighted average ordinary shares outstanding — 4,375,000 Basic and diluted net loss per ordinary share $ — $ (0.00 ) Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying unaudited condensed consolidated financial statements.

Initial Public Offering

Initial Public Offering	4 Months Ended	9 Months Ended
	Dec. 31, 2020	Sep. 30, 2021
FS DEVELOPMENT CORP. II
Initial Public Offering	Note 3 — Proposed Public Offering Pursuant to the Proposed Public Offering, the Company intends to offer for sale 10,000,000 shares of Class A Common stock at a price of $10.00 per share. The Company will grant the underwriters a 45-day	Note 3 — Initial Public Offering On February 19, 2021, the Company consummated its Initial Public Offering of 20,125,000 Public Shares, including the issuance of 2,625,000 shares as a result of the underwriter’s exercise in full of its over-allotment option, at $10.00 per share, generating gross proceeds of approximately $201.3 million, and incurring offering costs of approximately $11.5 million, of which approximately $7.0 million was for deferred underwriting commissions.

Related Party Transactions

Related Party Transactions	4 Months Ended	9 Months Ended
	Dec. 31, 2020	Sep. 30, 2021
Related Party Transactions		8. Related Party Transactions Consulting Arrangements Prior to raising capital in late 2020, the Company engaged two of the Company’s current executive officers as consultants pursuant to consulting agreements. For the period February 27, 2020 (inception) through December 31, 2020, the Company incurred approximately $0.1 million in fees pursuant to these agreements, all of which is recorded in general and administrative expenses in the accompanying statement of operations and comprehensive loss. As of December 31, 2020, approximately $0.1 million of this amount remained unpaid and was included in accounts payable on the accompanying balance sheet. For the nine months ended September 30, 2021 (unaudited), the Company incurred approximately $12,000 expenses pursuant to these agreements. All amounts owed under the consulting agreements were paid as of September 30, 2021 (unaudited). In addition, in January 2021, a former member of our Scientific Advisory Board became a member of the Company’s Board of Directors. For the period February 27, 2020 (inception) through December 31, 2020, the Company incurred approximately $5,000 in fees pursuant to a consulting agreement with this individual, all of which is recorded in research and development expenses in the accompanying statement of operations and comprehensive loss. As of December 31, 2020, approximately $700 remained unpaid and was included in accounts payable on the accompanying balance sheet. All amounts owed under the consulting agreement were paid as of September 30, 2021 (unaudited).
FS DEVELOPMENT CORP. II
Related Party Transactions	Note 4 — Related Party Transactions Founder Shares and Private Placement Shares On August 26, 2020, the Sponsor paid $25,000 to cover certain expenses on behalf of the Company in consideration of 2,875,000 shares of the Company’s Class B common stock, par value $0.0001 per share, (the “Founder Shares”). The Sponsor has agreed to forfeit up to 375,000 Founder Shares to the extent that the over-allotment option is not exercised in full by the underwriters. The forfeiture will be adjusted to the extent that the over-allotment option is not exercised in full by the underwriters so that the Founder Shares will represent 20.0% of the Company’s issued and outstanding shares of common stock after the Proposed Public Offering (excluding the Private Placement Shares). The Sponsor has agreed to purchase an aggregate of 400,000 Private Placement Shares (or 430,000 Private Placement Shares if the underwriters’ over-allotment option is exercised in full), at a price of $10.00 per Private Placement Share ($4.0 million in the aggregate, or $4.3 million if the underwriters’ over-allotment option is exercised in full) in a private placement that will occur simultaneously with the closing of the Proposed Public Offering. The Initial Stockholders have agreed, subject to limited exceptions, not to transfer, assign or sell any of the Founder Shares until the earlier to occur of: (i) one year after the completion of the initial Business Combination and (ii) the date following the completion of the initial Business Combination on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the stockholders having the right to exchange their common stock for cash, securities or other property and the Sponsor has agreed not to transfer, assign or sell any of its Private Placement Shares until 30 days after the completion of the initial Business Combination. Notwithstanding the foregoing, if the closing price of the Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading Related Party Loans On August 26, 2020, the Sponsor agreed to loan the Company an aggregate of up to $200,000 to cover expenses related to the Proposed Public Offering pursuant to a promissory note, as amended (the “Note”). This loan is non-interest In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination or, at the lender’s discretion, up to $1.5 million of such Working Capital Loans may be convertible into shares of Class A common stock of the post-Business Combination entity at a price of $10.00 per share. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. To date, the Company had no borrowings under the Working Capital Loans. Private Placement of Common Stock in connection with initial Business Combination The Sponsor has indicated an interest to purchase $25.0 million of the Company’s Class A common stock in a private placement that would occur concurrently with the consummation of the initial Business Combination. The funds from such private placement would be used as part of the consideration to the sellers in the initial Business Combination, and any excess funds from such private placement would be used for working capital in the post-transaction company. However, because indications of interest are not binding agreements or commitments to purchase, the Sponsor may determine not to purchase any such shares, or to purchase fewer shares than it indicated an interest in purchasing. Furthermore, the Company is not under any obligation to sell any such shares. Administrative Services Agreement The Company will enter into an agreement that provides that, commencing on the date that the Company’s securities are first listed on Nasdaq and continuing until the earlier of the Company’s consummation of a Business Combination and the Company’s liquidation, the Company will pay the Sponsor a total of $10,000 per month for office space, secretarial and administrative services provided to members of the Company’s management team. The Sponsor, officers and directors, or any of their respective affiliates will be reimbursed for any out-of-pocket	Note 4 — Related Party Transactions Founder Shares and Private Placement Shares On August 26, 2020, the Sponsor paid $25,000 to cover certain offering costs on behalf of the Company in consideration of 2,875,000 shares (the “Founder Shares”) of the Company’s Class B common stock, par value $0.0001 per share (“Class B Common Stock”). On January 22, 2021, the Sponsor transferred 30,000 Founder Shares to each of Dr. Dubin, Mr. Hughes and Dr. Pakianathan, at their original per-share 1 2 1 6 Simultaneously with the closing of the Initial Public Offering, the Company consummated the Private Placement of 602,500 Private Placement Shares, at a price of $10.00 per Private Placement Share to the Sponsor, generating proceeds of approximately $6.0 million. The Initial Stockholders agreed, subject to limited exceptions, not to transfer, assign or sell any of the Founder Shares until the earlier to occur of (ii) the date following the completion of the initial Business Combination on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the stockholders having the right to exchange their common stock for cash, securities or other property and the Sponsor agreed not to transfer, assign or sell any of its Private Placement Shares until 30 days after the completion of the initial Business Combination. Notwithstanding the foregoing, if the closing price of the Class A Common Stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day Related Party Loans On August 26, 2020, the Sponsor agreed to loan the Company an aggregate of up to $200,000 to cover expenses related to the Initial Public Offering pursuant to a promissory note, as amended (the “Note”). This loan was non-interest In addition, in order to finance transaction costs in connection with a Business Combination, the Sponsor, or an affiliate of the Sponsor, or certain of the Company’s officers and directors may, but are not obligated to, loan the Company funds as may be required (“Working Capital Loans”). If the Company completes a Business Combination, the Company would repay the Working Capital Loans out of the proceeds of the Trust Account released to the Company. Otherwise, the Working Capital Loans would be repaid only out of funds held outside the Trust Account. In the event that a Business Combination does not close, the Company may use a portion of proceeds held outside the Trust Account to repay the Working Capital Loans but no proceeds held in the Trust Account would be used to repay the Working Capital Loans. The Working Capital Loans would either be repaid upon consummation of a Business Combination or, at the lenders’ discretion, up to $1.5 million of such Working Capital Loans may be convertible into shares of Class A Common Stock of the post-Business Combination entity at a price of $10.00 per share. Except for the foregoing, the terms of such Working Capital Loans, if any, have not been determined and no written agreements exist with respect to such loans. As of September 30, 2021 and December 31, 2020, the Company had no borrowings under the Working Capital Loans. Subscription Agreement In connection with the proposed business combination, the Company entered in a subscription agreement with two related parties, each subscribing to purchase shares of Class A Common Stock in the amount of $5,000,000 ($10,000,000 in aggregate) at the closing date of the proposed business combination. Administrative Services Agreement Commencing on the date that the Company’s securities were first listed on Nasdaq and continuing until the earlier of the Company’s consummation of a Business Combination and the Company’s liquidation, the Company agreed to pay the Sponsor, or an affiliate a total of $10,000 per month for office space, secretarial and administrative services provided to members of the Company’s management team. The Company incurred approximately $30,000, $80,000 and $0 in administrative expenses under the agreement, which is recognized in the accompanying unaudited condensed consolidated statements of operations for the three and nine months ended June 30, 2021, and for the period from August 21, 2020 (inception) through September 30, 2020, respectively, within general and administrative expense — related party. As of September 30, 2021 and December 31, 2020, there was no outstanding balance in accounts payable with related party, as reflected in the accompanying condensed consolidated balance sheets. The Sponsor, officers and directors, or any of their respective affiliates will be reimbursed for any out-of-pocket

Commitments and Contingencies

Commitments and Contingencies	4 Months Ended	9 Months Ended
	Dec. 31, 2020	Sep. 30, 2021
Commitments and Contingencies		7. Commitments and Contingencies Contingencies From time to time, the Company may become subject to claims or suits arising in the ordinary course of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. As of December 31, 2020 and September 30, 2021 (unaudited), the Company was not a party to any litigation.
Fs Development Corp II [Member]
Commitments and Contingencies	Note 5 — Commitments and Contingencies Registration Rights The holders of Founder Shares, Private Placement Shares to be issued in the private placement that will occur simultaneously with the closing of the Proposed Public Offering, and shares of Class A common stock that may be issued upon conversion of Working Capital Loans, if any, will be entitled to registration rights pursuant to the Prior Registration Rights Agreement. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Underwriting Agreement The underwriters are entitled to an underwriting discount of $0.20 per share, or $2.0 million in the aggregate (or $2.3 million in the aggregate if the underwriters’ over-allotment option is exercised in full), payable upon the closing of the Proposed Public Offering. In addition, $0.35 per share, or $3.5 million in the aggregate (or approximately $4.0 million in the aggregate if the underwriters’ over-allotment option is exercised in full) will be payable to the underwriters for deferred underwriting commissions. The deferred fee will become payable to the underwriters from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. Risks and Uncertainties Management continues to evaluate the impact of the COVID-19	Note 5 — Commitments and Contingencies Registration Rights The holders of Founder Shares, Private Placement Shares, and shares of Class A Common Stock that may be issued upon conversion of Working Capital Loans, if any, are entitled to registration rights pursuant to a registration rights agreement. The holders of these securities are entitled to make up to three demands, excluding short form demands, that the Company register such securities. In addition, the holders have certain “piggy-back” registration rights with respect to registration statements filed subsequent to the completion of the initial Business Combination. The Company will bear the expenses incurred in connection with the filing of any such registration statements. Underwriting Agreement The Company granted the underwriter a 45-day The underwriter was entitled to an underwriting discount of $0.20 per share, or approximately $4.0 million in the aggregate, paid upon the closing of the Initial Public Offering. In addition, $0.35 per share, or approximately $7.0 million in the aggregate will be payable to the underwriter for deferred underwriting commissions. The deferred fee will become payable to the underwriter from the amounts held in the Trust Account solely in the event that the Company completes a Business Combination, subject to the terms of the underwriting agreement. Risks and Uncertainties Management continues to evaluate the impact of the COVID-19

Class A Common Stock Subject to

Class A Common Stock Subject to Possible Redemption	9 Months Ended
	Sep. 30, 2021
FS DEVELOPMENT CORP. II
Class A Common Stock Subject to Possible Redemption	Note 6 — Class A Common Stock Subject to Possible Redemption The Company’s Class A common stock feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence of future events. The Company is authorized to issue 100,000,000 shares of Class A common stock with a par value of $0.0001 per share. Holder of the Company’s Class A common stock are entitled to one vote for each share. Accordingly, there were 20,125,000 shares of Class A common stock subject to possible redemption. The Class A common stock subject to possible redemption reflected on the balance sheet is reconciled on the following table: Gross proceeds from Initial Public Offering $ 201,250,000 Less: Offering costs allocated to Class A common stock subject to possible redemption (11,455,480 ) Plus: Accretion of carrying value to redemption value 11,455,480 Class A common stock subject to possible redemption $ 201,250,000

Stockholders' Deficit

Stockholders' Deficit	4 Months Ended	9 Months Ended
	Dec. 31, 2020	Sep. 30, 2021
Stockholders' Equity		5. Stockholders’ Deficit Amended and Restated Articles of Incorporation On January 19, 2021, the Company amended and restated its restated certificate of incorporation to increase its authorized shares of common stock from 10,000,000 to 25,187,755 shares and created a new class of preferred shares authorizing 13,923,367 shares as Preferred Stock, designating 9,771,425 shares as Series A Preferred Stock, 2,818,034 shares as Series A-1 A-2 A-3 Convertible Preferred Stock Sale of Convertible Preferred Stock In January 2021, the Company sold 9,771,414 shares of Series A Preferred Stock for gross proceeds of $44.5 million and issued a total of 4,151,942 shares of Series A-1, A-2 A-3 As of September 30, 2021 (unaudited), convertible preferred stock consisted of (in thousands, except share and per-share Shares Shares Per Share Liquidation Carrying Series A 9,771,425 9,771,414 $ 4.5541 $ 44,500 $ 44,323 Series A-1 2,818,034 2,818,034 $ 1.2420 3,500 9,638 Series A-2 605,850 605,850 $ 2.4841 1,505 2,302 Series A-3 728,058 728,058 $ 2.8981 2,110 2,869 Total 13,923,367 13,923,356 $ 51,615 $ 59,132 The rights, preferences and privileges of the convertible preferred stock as of September 30, 2021 (unaudited) were as follows: Voting Rights The holders of preferred stock are entitled to vote, together with the holders of common stock, on all matters submitted to the stockholders for a vote and are entitled to the number of votes equal to the number of whole shares of common stock into which such holders of preferred stock could convert on the record date for determination of stockholders entitled to vote. Dividends The Company cannot declare and pay any common stock dividends without first declaring and paying dividends, as defined in the terms of the Company’s amended and restated certificate of incorporation, to the preferred stockholders. The holders of preferred stock are entitled to receive, when, as and if declared by the Board of Directors, noncumulative dividends at the rate of 8.0% of the applicable original issue price of such preferred stock (Original Issue Price), subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the preferred stock. No dividends have been declared as of September 30, 2021 (unaudited). Liquidation Rights In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company or Deemed Liquidation Event (as defined in the Company’s amended and restated certificate of incorporation), each holder of preferred stock is entitled to receive, prior and in preference to any distributions to the common stockholders, an amount equal to the greater of (i) the Original Issue Price per share, plus any declared but unpaid dividends thereon or (ii) the amount such holder would have received if such holder had converted its shares into common stock immediately prior to such liquidation event. In the event that the assets available for distribution to the holders of preferred stock are insufficient to pay such holders the full amounts to which they are entitled, the assets available for distribution will be distributed on a pro rata basis among the holders of the preferred stock in proportion to the respective amounts that would otherwise be payable in respect of such stock. After payments have been made in full to the holders of preferred stock, then, to the extent available, the remaining amounts would be distributed among the holders of the common stock, pro rata based on the number of shares held by each holder. Conversion Rights The shares of preferred stock are convertible into an equal number of shares of common stock, at the option of the holder, subject to certain anti-dilution adjustments. Each share of preferred stock is automatically converted into common stock (A) upon the closing of a firmly underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, covering the offer and sale of common stock for the account of the Company in which the pre-money Presentation of Convertible Preferred Stock The Company’s convertible preferred stock has been classified as temporary equity in the accompanying balance sheet in accordance with authoritative guidance for the classification and measurement of potentially redeemable securities whose redemption is based upon certain change in control events outside of the Company’s control, including liquidation, sale or transfer of control of the Company. The Company has determined not to adjust the carrying values of the convertible preferred stock to the liquidation preferences of such shares because the occurrence of any such change in control event is not probable. In addition, a member of the executive team was a 2020 SAFE investor and is currently a Series A preferred stockholder. Common Stock In 2020, the Company sold 6,983,000 shares of restricted common stock to officers and employees of the Company and consultants to the Company during the Company’s formation period. The proceeds from the restricted common stock sale were immaterial to the financial statements. The stock is subject to vesting, generally at 25% one year from the vesting commencement date and ratably each month thereafter for a period of 36 months. At December 31, 2020, there were 6,850,000 remaining shares issued, of which no shares were vested and outstanding. At December 31, 2020 and September 30, 2021 (unaudited), the repurchase liability for these shares was nominal. For accounting purposes, the unvested shares purchased are not deemed to be outstanding. A summary of the restricted common stock awards is as follows: Number of Balance at February 27, 2020 (inception) — Issued shares 6,983,000 Forfeited shares (133,000 ) Balance at December 31, 2020 6,850,000 Issued shares (unaudited) 75,000 Vested shares (unaudited) (2,376,715 ) Balance at September 30, 2021 (unaudited) 4,548,285 2020 Equity Incentive Plan In March 2020, the Company adopted the 2020 Stock Plan (as amended, the Plan). The Plan provides for the grant of incentive stock options, non-statutory Stock option activity for employee and nonemployee awards and related information is as follows: Number Weighted- Weighted- Weighted- Aggregate Outstanding at December 31, 2020 — — Granted (unaudited) 1,718,433 $ 5.63 $ 3.91 Exercised (unaudited) (1,000 ) $ 4.44 Canceled (unaudited) (112,500 ) $ 5.42 Outstanding and expected to vest at September 30, 2021 (unaudited) 1,604,933 $ 5.64 9.6 $ 3.92 $ 5,824 Vested and exercisable at September 30, 2021 (unaudited) 9,248 $ 6.02 9.8 $ 4.05 $ 30 During the period February 27, 2020 (inception) through December 31, 2020, 9,000 shares of restricted common stock were granted at fair value under the Plan, of which 6,000 shares remain unvested as of September 30, 2021 (unaudited). The stock-based compensation expense associated with the restricted common stock was immaterial to the financial statements for the period February 27, 2020 (inception) through December 31, 2020 and the nine months ended September 30, 2021 (unaudited). Stock-Based Compensation Expense The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the stock options granted in the nine months ended September 30, 2021 (unaudited) were as follows: Assumed risk-free interest rate 1.1 % Assumed volatility 80.8 % Expected option life (in years) 6.2 Expected dividend yield — % Risk-free interest rate. zero-coupon Expected volatility. Expected term. Expected dividend yield. The allocation of stock-based compensation expense for the nine months ended September 30, 2021 (unaudited) was as follows (in thousands): Research and development $ 246 General and administrative 404 Total stock-based compensation $ 650 As of September 30, 2021 (unaudited), the unrecognized compensation cost related to outstanding time-based options was $5.6 million, which is expected to be recognized over a weighted-average period of 3.5 years. Common Stock Reserved for Future Issuance Common stock reserved for future issuance consists of the following: December 31, September 30, (unaudited) Conversion of outstanding convertible preferred stock — 13,923,356 Outstanding stock options — 1,604,933 Shares available for issuance under the Plan 991,000 1,525,051 Total 991,000 17,053,340
FS DEVELOPMENT CORP. II
Stockholders' Equity	Note 6 — Stockholder’s Equity Class A Common Stock Class B Common Stock Holders of record of Class A common stock and Class B common stock will vote together as a single class on all matters submitted to a vote of our stockholders, with each share of common stock entitling the holder to one vote except as required by law. The Class B common stock will automatically convert into Class A common stock concurrently with or immediately following the consummation of the initial Business Combination on a one-for-one as-converted stock issued, or deemed issued or issuable upon conversion or exercise of any equity-linked securities or rights issued or deemed issued, by the Company in connection with or in relation to the consummation of the initial Business Combination, excluding any shares of Class A common stock or equity-linked securities or rights exercisable for or convertible into shares of Class A common stock issued, or to be issued, to any seller in the initial Business Combination and any Private Placement Shares issued to the Sponsor, officers or directors upon conversion of Working Capital Loans, provided that such conversion of Founder Shares will never occur on a less than one-for-one Preferred Stock	Note 7 — Stockholders’ Equity Preferred Stock — Class A Common Stock Class B Common Stock The Class B Common Stock will automatically convert into Class A Common Stock concurrently with or immediately following the consummation of the initial Business Combination on a one-for-one as-converted one-for-one

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2021
Fair Value Measurements	3. Fair Value Measurements The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: Level 1 Level 2 Level 3 At December 31, 2020 and September 30, 2021 (unaudited), the Company did not have financial assets that are measured at fair value on a recurring basis. As further described in Note 4, between April 2020 and December 2020, the Company entered into several Simple Agreements for Future Equity (SAFE, collectively the “2020 SAFEs”) with certain investors. The Company recorded the liability related to the 2020 SAFEs at fair value and subsequently remeasured the instruments to fair value using level 3 fair value measurements. The fair value of the 2020 SAFEs was determined based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The Company determined the fair value of the 2020 SAFEs based on the amount of proceeds received from new third-party investors for the 2020 SAFEs, the terms of the 2020 SAFEs, including the rate at which the 2020 SAFEs convert into qualified equity financing securities, the probability and timing of a qualified equity financing and the fair value of the underlying preferred stock. Estimates and assumptions impacting the fair value measurement include the probability of a qualified equity financing as defined in the 2020 SAFEs agreements, the expected timing of such event, and the fair value of the Company’s Series A preferred stock (the “Series A Preferred”). The Company estimated the probability and timing of the qualified equity financing based on management’s assumptions and knowledge of specified events at issuance and as of each reporting date. The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands): 2020 SAFEs issued in the 2020 period $ 7,115 Change in fair value during the 2020 period 7,693 Balance as of December 31, 2020 14,808 Conversion into shares of convertible preferred stock (unaudited) (14,808 ) Balance as of September 30, 2021 (unaudited) $ —
FS DEVELOPMENT CORP. II
Fair Value Measurements	Note 8 — Fair Value Measurements The following table presents information about the Company’s assets that are measured at fair value on a recurring basis as of September 30, 2021 and indicates the fair value hierarchy of the valuation techniques that the Company utilized to determine such fair value. Description Quoted Significant Significant Investments held in Trust Account – money market funds $ 201,262,131 $ — $ — Transfers to/from Levels 1, 2, and 3 are recognized at the beginning of the reporting period. There were no transfers between levels of the hierarchy for the three and nine months ended September 30, 2021. Level 1 instruments include investments in money market funds that invest solely in U.S. government securities with an original maturity of 185 days or less.

Simple Agreements for Future Eq

Simple Agreements for Future Equity	9 Months Ended
	Sep. 30, 2021
Simple Agreements For Future Equity [Abstract]
Simple Agreements for Future Equity	4. Simple Agreements for Future Equity Between April 2020 and December 2020, the Company entered into several SAFEs with certain investors, pursuant to which the Company received funding of $7.1 million in cash in exchange for 4,151,942 SAFE shares providing the investors the right to receive shares of the Company’s capital stock. The 2020 SAFEs contained a number of conversion and redemption provisions, including settlement upon liquidity or dissolution events. The 2020 SAFEs required that the Company issue equity to the SAFE holders in exchange for their investment upon an equity financing. An equity financing was defined as a transaction or series of transactions with the principal purpose of raising capital, pursuant to which the Company issued and sold preferred stock at a fixed valuation. The number of shares to be received by the 2020 SAFE investors was determined as the greater of the SAFE purchase amount divided by (i) the lowest price per share of the Series A preferred stock or (ii) the SAFE purchase amount divided by the SAFE price per share. A liquidity event meant a change in control, a direct listing, or an Initial Public Offering. In a liquidity or dissolution event, the investors’ right to receive cash out was junior to payment of outstanding indebtedness and creditor claims, on par for other SAFEs and preferred stock, and senior to common stock. The 2020 SAFEs had no interest rate or maturity date, and the 2020 SAFE investors had no voting right prior to conversion. As of December 31, 2020, the 2020 SAFEs had not yet converted as an equity financing had not yet occurred. The Company determined that the 2020 SAFEs should be recorded as a liability at fair value on the Company’s balance sheet and remeasured at each reporting date. As of December 31, 2020, the fair value of the 2020 SAFEs was $14.8 million. Due to a short period where the Company expected these to be converted, the Company recorded the entire amount of $14.8 million as a short-term liability. The Company recorded changes in the fair value of the 2020 SAFEs in other expense in the statements of operations and comprehensive loss, which was $7.7 million for the period between the initial SAFE issuance in April 2020 and December 31, 2020. See Note 3 — Fair Value Measurements. Between April 2020 and September 2020, the Company entered into two SAFEs with certain investors, pursuant to which the Company received funding of approximately $5.0 million in cash in exchange for the investors right to receive shares of the Company’s capital stock. As of September 30, 2020, the fair value of the 2020 SAFEs was determined to be approximately $5.9 million. The Company recorded changes in the fair value of the 2020 SAFEs in other expense in the statements of operations and comprehensive loss, which was $0.9 million for the period between the initial SAFE issuance in April 2020 and September 30, 2020. The 2020 SAFEs were automatically converted on January 19, 2021 into 2,818,034 shares of Series A-1 A-2 A-3 A-1 A-2 A-3

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Income Tax	6. Income Taxes For the period February 27, 2020 (inception) to December 31, 2020, and for the period February 27, 2020 (inception) through September 30, 2020 and the nine months ended September 30, 2021 (unaudited), due to the operating losses reported and the full valuation allowance recorded on the Company’s net deferred income tax assets, the Company recorded no provision for income taxes. A reconciliation of the Company’s income taxes to the amount computed by applying the statutory federal income tax rate to the pretax loss for the period February 27, 2020 (inception) to December 31, 2020 is summarized as follows (in thousands): Expected income tax benefit at statutory rates $ (2,731 ) Permanent items 35 Change in fair value of 2020 SAFEs 1,616 Research credits (32 ) Valuation allowance 1,112 $ — As of December 31, 2020, significant components of the Company’s deferred income taxes are as follows (in thousands): Deferred tax assets: Net operating loss carryforward $ 1,078 Research credit carryforwards 31 Other, net 3 Total deferred tax assets 1,112 Less valuation allowance (1,112 ) Net deferred tax assets $ — The Company has established a full valuation allowance of $1.1 million against its net deferred tax assets due to the uncertainty surrounding the realization of such assets that preclude it from determining that it is more likely than not that such assets will be realized. The Company periodically evaluates the recoverability of the deferred tax assets. At such time as it is determined that it is more likely than not that deferred assets are realizable, the valuation allowance will be reduced. Management’s assessment as of December 31, 2020 considered the generation of pre-tax tax-planning As of December 31, 2020, the Company had federal net operating loss (NOL) carryforwards of approximately $5.1 million, before consideration of limitations under Section 382 of the Internal Revenue Code of 1986, as amended (IRC), as further described below, that will carryforward indefinitely. Additionally, as of December 31, 2020, the Company had state NOL carryforwards of approximately $5.1 million which may be used to offset future taxable income and will begin to expire in 2040. As of December 31, 2020, the Company had federal and state tax credit carryforwards of approximately $52,000. The Company has not performed a formal research and development credit study with respect to these credits. The state credits carry forward indefinitely. Pursuant to IRC Section 382 and IRC Section 383, the Company’s ability to use NOL and R&D tax credit carry forwards (tax attribute carry forwards) to offset future taxable income is limited if the Company experiences a cumulative change in ownership of more than 50% within a three-year testing period. The Company has not completed an ownership change analysis pursuant to IRC Section 382. If ownership changes within the meaning of IRC Section 382 are identified as having occurred, the amount of remaining tax attribute carry-forwards available to offset future taxable income and income tax expense in future years may be significantly restricted or eliminated. Further, deferred tax assets associated with such tax attributes could be significantly reduced upon realization of an ownership change within the meaning of IRC Section 382. As of December 31, 2020, the Company has an unrecognized tax benefit balance of $0.5 million related to federal and state tax credits and state NOLs. Due to the existence of the full valuation allowance, future changes in unrecognized tax benefits will not impact the Company’s effective tax rate. The Company does not foresee material changes to its liability for uncertain tax benefits within the next 12 months. The Company’s policy is to include interest and penalties related to unrecognized income tax benefits as a component of income tax expense. The Company has no accruals for interest or penalties in the accompanying balance sheet as of December 31, 2020 and has not recognized interest or penalties in the accompanying statement of operations for the period February 27, 2020 (inception) through December 31, 2020. Prior to 2021, the Company was subject to taxation in the United States and California. The Company is subject to examination by these taxing authorities since inception due to the net operating loss carryovers. Beginning in 2021, the Company is also subject to taxation and examination in Indiana, Massachusetts, New Jersey and Texas. CARES Act and Consolidated Appropriations Act On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 On December 27, 2020, the Consolidated Appropriations Act 2021 (CAA) was also enacted in response to the COVID-19

401(k) Plan

401(k) Plan	9 Months Ended
	Sep. 30, 2021
Retirement Benefits [Abstract]
Defined Contribution Plan	9. 401(k) Plan The Company established a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code of 1986, as amended (“Code”). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. The Company has not made any contributions to the 401(k) Plan for the period February 27, 2020 (inception) through December 31, 2020 or for the nine months ended September 30, 2021 (unaudited).

Subsequent Events

Subsequent Events	1 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2021
Subsequent Events		10. Subsequent Events The Company has evaluated subsequent events through July 20, 2021, the date when the audited financial statements were issued. For the purposes of the interim financial statements as of and for the nine months ended September 30, 2021, the Company has evaluated the subsequent events through November 16, 2021 (unaudited), the date the interim financial statements were issued. Except as described below or elsewhere in these financial statements, the Company has concluded that no subsequent events have occurred that require disclosure. Merger of FS Development On June 29, 2021, the Company executed a definitive business combination agreement, as amended on November 7, 2021, between it and FS Development Corp. II (the “Merger Agreement”). As a result of the proposed business combination, FS Development Corp. II will be renamed to Pardes Biosciences, Inc., or Combined Entity, and the Company will become a wholly owned subsidiary of Combined Entity. Upon the completion of the proposed business combination transaction, the shareholders of the Company will exchange their interests for shares of common stock of Combined Entity. In addition, the Company’s existing equity incentive plan will be terminated and awards issued under the Company’s existing equity incentive plan will be exchanged for awards issued under a new equity incentive plan to be adopted by Combined Entity. Immediately after the completion of the business combination, certain investors have agreed to subscribe for and purchase an aggregate of $75.0 million of common stock of Combined Entity. The Combined Entity is expected to receive gross proceeds of approximately $276.0 million at the closing of the transaction (assuming no redemptions are effected by shareholders of FS Development Corp. II) and will continue to operate under the Company’s management team, led by chief executive officer Uri A. Lopatin, M.D. The boards of directors of both FS Development Corp. II and the Company have approved the proposed transaction. Completion of the transaction, which is expected in the fourth quarter of 2021, is subject to approval of FS Development Corp. II’s shareholders and the satisfaction or waiver of certain other customary closing conditions. In addition, certain investors in FS Development Corp. II and the additional common stock sale are currently Series A preferred stockholders. Convertible Notes Effective November 10, 2021, directors, including all of Pardes’s disinterested directors, unanimously approved the execution and delivery of a convertible note purchase agreement providing for the purchase and sale of up to $25.0 million of unsecured convertible promissory term notes (the “Convertible Notes”) to purchasers at one or more closings, including existing stockholders of the Company. As of the initial closing, the Company has issued Convertible Notes for an aggregate principal amount of $10.0 million. The Convertible Notes accrue interest at the annual rate of 4% per annum, mature on October 31, 2022 and will be due and payable at the earlier of the closing under the Merger Agreement, the closing of a “corporate transaction” and at any time on or after the maturity date at Pardes’ election or upon demand of a purchaser. If the Merger Agreement is terminated, the Convertible Notes will be convertible at a fifteen percent (15%) discounted price into the Company equity securities sold in the next round of equity financing by Pardes that meets certain requirements. The Company will use proceeds from the closing of the transactions contemplated under the Merger Agreement to repay outstanding principal amounts and accrued and unpaid interest under the outstanding Convertible Notes as of the closing. As of November 15, 2021, stockholders of Pardes affiliated with the Sponsor and FS Development II have purchased $10.0 million in Convertible Notes.
FS DEVELOPMENT CORP. II
Subsequent Events	Note 7 — Subsequent Events On January 22, 2021, the Sponsor transferred 30,000 Founder Shares to certain independent director nominees, Dr. Dubin, Mr. Hughes and Dr. Pakianathan, at their original per-share The Company evaluated subsequent events and transactions that occurred after the balance through January 26, 2021, the date that the financial statements were available to be issued. Based on this review, except as noted above, the Company did not identify any subsequent events that would have required adjustment or disclosure in the financial statements.	Note 9 — Subsequent Events The Company evaluated subsequent events and transactions that occurred up to the date the condensed consolidated financial statements were available to be issued. Based upon this review, the Company determined that there have been no events that have occurred that would require adjustments to the disclosures in the unaudited condensed consolidated financial statements.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	4 Months Ended	9 Months Ended
	Dec. 31, 2020	Sep. 30, 2021
Unaudited Interim Financial Information		Unaudited Interim Financial Information The accompanying interim balance sheet as of September 30, 2021, and the statements of operations and comprehensive loss, statements of convertible preferred stock and stockholders’ deficit and cash flows for the period February 27, 2020 (inception) through September 30, 2020 and for the nine months ended September 30, 2021 are unaudited. In management’s opinion, the unaudited interim financial statements have been prepared on the same basis as the audited financial statements and reflect all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of September 30, 2021 and the results of its operations and its cash flows for the period February 27, 2020 (inception) through September 30, 2020 and for the nine months ended September 30, 2021 in accordance with U.S. GAAP. The financial data and other information disclosed in these notes related to the period February 27, 2020 (inception) through September 30, 2020 and for the nine months ended September 30, 2021 are also unaudited. The results for the Company during the interim periods are not necessarily indicative of the results expected for the full fiscal year or any other interim period.
Use of Estimates		Use of Estimates The preparation of the Company’s financial statements requires the Company to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. Such estimates include the valuation of the Simple Agreements for Future Equity (SAFE) agreements, the valuation of stock-based awards and accrual of research and development expenses. Management evaluates its estimates on an ongoing basis. Although estimates are based on the Company’s historical experience, knowledge of current events, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.
Cash and Cash Equivalents		Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents.
Concentration of Credit Risk		Concentration of Credit Risk Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash and money market accounts. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.
Comprehensive Loss		Comprehensive Loss Comprehensive loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner
Deferred Offering Costs		Deferred Offering Costs The Company capitalizes costs that are directly associated with in-process in-process
Fair Value of Financial Instruments		Fair Value of Financial Instruments The carrying amounts of cash and cash equivalents, prepaid expenses and other current assets, accounts payable, and accrued expenses are considered to be representative of their respective fair values because of the short-term nature of those instruments. Prior to their conversion, the Company remeasured its SAFE agreements to fair value each reporting period (see Note 3).
Accrued Research and Development Expense		Accrued Research and Development Expense The Company is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants, and contract research organizations, in connection with conducting research and development activities. The financial terms of these contracts vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company reflects research and development expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the preclinical study as measured by the timing of various aspects of the study or related activities. The Company determines accrual estimates through review of the underlying contracts along with discussions with research and other key personnel as to the progress of studies, or other services being conducted. During the course of a study, the Company adjusts its rate of expense recognition if actual results differ from its estimates.
Research and Development Expenses		Research and Development Expenses Research and development expenses are charged to expense as incurred. Research and development expenses primarily consist of costs incurred for services provided by outside organizations and consultants for preclinical and clinical activities, salaries and related expenses for personnel performing research and development activities, and supplies used in research and development activities.
Patent Costs		Patent Costs Costs related to filing and pursuing patent applications are recorded as general and administrative expense and expensed as incurred since recoverability of such expenditures is uncertain.
Stock-Based Compensation		Stock-Based Compensation Stock-based compensation expense represents the grant date fair value of employee and non-employee For restricted stock awards, the fair value of the award is the estimated fair value of the Company’s common stock on the grant date. The fair value of the shares of common stock has historically been determined by the Company’s board of directors as there was no public market for the common stock. The board of directors determines the fair value of the common stock by obtaining third-party valuations of the Company’s common stock using the option pricing method and the probability-weighted expected return method. Significant assumptions used in determining the fair value of common stock include volatility, discount for lack of marketability, and the expected timing of a future liquidity event.
Income Taxes		Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company recognizes deferred tax assets to the extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning As of December 31, 2020 and for all periods presented, the Company maintained a valuation allowance against its deferred tax assets as the Company concluded it had not met the “more likely than not” to be realized threshold. Changes in the valuation allowance when they are recognized in the provision for income taxes may result in a change in the estimated annual effective tax rate. The Company records uncertain tax positions on the basis of a two-step more-likely-than-not ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits within income tax expense. Any accrued interest and penalties are included within the related tax lia
Segment Reporting		Segment Reporting Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. The chief operating decision maker is the chief executive officer. The Company views its operations and manages its business as one operating segment and one reportable segment. No product revenue has been generated since inception and all assets are held in the United States.
Net Loss Per Share		Net Loss Per Share Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding for the period. There were no common shares outstanding as of December 31, 2020 and September 30, 2020 (unaudited). Basic and diluted net loss attributable to common stockholders per share is presented in conformity with the two-class Diluted net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares and dilutive common stock equivalents outstanding for the period. Common stock equivalents are only included when their effect is dilutive. For the period presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding due to the Company’s net loss position. Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares): February 27, February 27, Nine (unaudited) Conversion of outstanding convertible preferred stock — — 13,923,356 Outstanding stock options — — 1,604,933 Restricted common stock subject to repurchase or forfeiture 6,859,000 6,261,500 4,554,285 Total 6,859,000 6,261,500 20,082,574
FS DEVELOPMENT CORP. II[Member]
Basis of Presentation	Basis of Presentation The accompanying financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. The Company does not have sufficient liquidity to meet its anticipated obligations over the next year from the issuance of these financial statements. In connection with the Company’s assessment of going concern considerations in accordance with FASB’s Accounting Standards Update (“ASU”) 2014-15,	Basis of Presentation The accompanying unaudited condensed consolidated financial statements are presented in U.S. dollars in conformity with accounting principles generally accepted in the United States of America (“GAAP”) for financial information and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP. In the opinion of management, the unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Operating results for the three and nine months ended September 30, 2021 are not necessarily indicative of the results that may be expected through December 31, 2021 or any future periods. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Form 8-K
Restatement of Previously Reported Financial Statements		Restatement of Previously Reported Financial Statements In preparation of the Company’s unaudited condensed consolidated financial statements for the quarterly period ended September 30, 2021, the Company concluded it should restate its previously issued financial statements to classify all Public Shares in temporary equity. In accordance with the SEC and its staff’s guidance on redeemable equity instruments in ASC 480-10-S99, In accordance with SEC Staff Accounting Bulletin No. 99, “Materiality,” and SEC Staff Accounting Bulletin No. 108, “Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements,” the Company evaluated the corrections and has determined that the related impact was material to the previously filed financial statements that contained the error, reported in the Company’s Form 8-K “Post-IPO Form 10-Qs The impact of the restatement to the Post-IPO paid-in As of February 19, 2021 As Previously Adjustment As Restated Total assets $ 203,119,261 $ 203,119,261 Total liabilities $ 7,351,899 $ 7,351,899 Class A common stock subject to possible redemption 190,767,360 10,482,640 201,250,000 Preferred stock — — — Class A common stock 165 (105 ) 60 Class B common stock 503 — 503 Additional paid-in 5,051,492 (5,051,492 ) — Accumulated deficit (52,158 ) (5,430,983 ) (5,483,201 ) Total stockholders’ equity (deficit) $ 5,000,002 $ (10,482,640 ) $ (5,482,638 ) Total Liabilities, Class A Common Stock Subject to Possible Redemption and Stockholders’ Equity (Deficit) $ 203,119,261 $ — $ 203,119,261 The impact of the restatement on the financial statements for the Affected Quarterly Periods is presented below. The table below presents the effect of the financial statement adjustments related to the restatement discussed above of the Company’s previously reported balance sheet as of March 31, 2021: As of March 31, 2021 As Previously Adjustment As Restated Total assets $ 202,959,356 $ 202,959,356 Total liabilities $ 7,284,061 $ 7,284,061 Class A common stock subject to possible redemption 190,675,290 10,574,710 201,250,000 Preferred stock — — — Class A common stock 166 (106 ) 60 Class B common stock 503 — 503 Additional paid-in 5,168,561 (5,168,561 ) — Accumulated deficit (169,225 ) (5,405,983 ) (5,575,268 ) Total stockholders’ equity (deficit) $ 5,000,005 $ (10,574,710 ) $ (5,574,705 ) Total Liabilities, Class A Common Stock Subject to Possible Redemption and Stockholders’ Equity (Deficit) $ 202,959,356 $ — $ 202,959,356 The Company’s statement of stockholders’ equity has been restated to reflect the changes to the impacted stockholders’ equity accounts described above. The table below presents the effect of the financial statement adjustments related to the restatement discussed above of the Company’s previously reported statement of cash flows for the three months ended March 31, 2021: Three Months Ended March 31, 2021 As Previously Adjustment As Restated Supplemental Disclosure of Noncash Financing Activities: Initial value of Class A common stock subject to possible redemption $ 190,767,360 $ (190,767,360 ) $ — Change in value of Class A common stock subject to possible redemption $ (92,070 ) $ 92,070 $ — The table below presents the effect of the financial statement adjustments related to the restatement discussed above of the Company’s previously reported balance sheet as of June 30, 2021: As of June 30, 2021 As Previously Adjustment As Restated Total assets $ 202,246,887 $ 202,246,887 Total liabilities $ 8,737,504 $ 8,737,504 Class A common stock subject to possible redemption 188,509,380 12,740,620 201,250,000 Preferred stock — — — Class A common stock 188 (128 ) 60 Class B common stock 503 — 503 Additional paid-in 7,334,449 (7,334,449 ) — Accumulated deficit (2,335,137 ) (5,405,983 ) (7,741,180 ) Total stockholders’ equity (deficit) $ 5,000,003 $ (12,740,620 ) $ (7,740,617 ) Total Liabilities, Class A Common Stock Subject to Possible Redemption and Stockholders’ Equity (Deficit) $ 202,246,887 $ — $ 202,246,887 The Company’s statement of stockholders’ equity has been restated to reflect the changes to the impacted stockholders’ equity accounts described above. The table below presents the effect of the financial statement adjustments related to the restatement discussed above of the Company’s previously reported statement of cash flows for the six months ended June 30, 2021: Six Months Ended June 30, 2021 As Previously Adjustment As Restated Supplemental Disclosure of Noncash Financing Activities: Initial value of Class A common stock subject to possible redemption $ 190,767,360 $ (190,767,360 ) $ — Change in value of Class A common stock subject to possible redemption $ (2,257,980 ) $ 2,257,980 $ — The impact to the reported amounts of weighted average shares outstanding and basic and diluted earnings per share is presented below for the Affected Quarterly Periods: Earnings Per Share As Previously Adjustment As Restated Three Months Ended March 31, 2021 Net loss $ (168,193 ) $ — $ (168,193 ) Weighted average shares outstanding – Class A common stock 20,727,500 (11,054,667 ) 9,672,833 Basic and diluted earnings per share – Class A common stock $ — $ (0.01 ) $ (0.01 ) Weighted average shares outstanding – Class B common stock 4,681,250 4,681,250 Basic and diluted earnings per share – Class B common stock $ (0.04 ) $ 0.03 $ (0.01 ) Earnings Per Share As Previously Adjustment As Restated Three Months Ended June 30, 2021 Net loss $ (2,165,912 ) $ — $ (2,165,912 ) Weighted average shares outstanding – Class A common stock 20,125,000 602,500 20,727,500 Basic and diluted earnings per share – Class A common stock $ — $ (0.08 ) $ (0.08 ) Weighted average shares outstanding – Class B common stock 5,633,750 5,031,250 Basic and diluted earnings per share – Class B common stock $ (0.38 ) $ 0.30 $ (0.08 ) Earnings Per Share As Previously Adjustment As Restated Six Months Ended June 30, 2021 Net loss $ (2,334,105 ) $ — $ (2,334,105 ) Weighted average shares outstanding – Class A common stock 20,125,000 (4,894,296 ) 15,230,704 Basic and diluted earnings per share – Class A common stock $ — $ (0.12 ) $ (0.12 ) Weighted average shares outstanding – Class B common stock 5,299,938 4,857,217 Basic and diluted earnings per share – Class B common stock $ (0.44 ) $ 0.32 $ (0.12 )
Emerging Growth Company	Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging	Emerging Growth Company The Company is an “emerging growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the independent registered public accounting firm attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statement, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.	Use of Estimates The preparation of financial statements in conformity with GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of December 31, 2020.	Cash and Cash Equivalents The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company had no cash equivalents as of September 30, 2021 and December 31, 2020.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage limit of $250,000. At December 31, 2020, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Deposit Insurance Corporation coverage limit of $250,000. As of September 30, 2021 and December 31, 2020, the Company had not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such accounts.
Investments Held in the Trust Account		Investments Held in the Trust Account The Company’s portfolio of investments is comprised of U.S. government securities, within the meaning set forth in Section 2(a)(16) of the Investment Company Act, with a maturity of 185 days or less, or investments in money market funds that invest in U.S. government securities and generally have a readily determinable fair value, or a combination thereof. When the Company’s investments held in the Trust Account are comprised of U.S. government securities, the investments are classified as trading securities. When the Company’s investments held in the Trust Account are comprised of money market funds, the investments are recognized at fair value. Trading securities and investments in money market funds are presented on the balance sheets at fair value at the end of each reporting period. Gains and losses resulting from the change in fair value of these securities is included in income on investments held in the Trust Account in the accompanying unaudited condensed consolidated statement of operations. The estimated fair values of investments held in the Trust Account are determined using available market information.
Fair Value Measurements		Fair Value Measurements Fair value is defined as the price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants at the measurement date. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: • Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; • Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and • Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The fair value of the Company’s assets and liabilities, which qualify as financial instruments under FASB ASC 820, “Fair Value Measurements and Disclosures,” approximates the carrying amounts represented in the balance sheet primarily due to their short-term nature.
Offering Costs Associated with the Initial Public Offering	Deferred Offering Costs Associated with the Proposed Public Offering Deferred offering costs consist of legal fees incurred through the balance sheet date that are directly related to the Proposed Public Offering and that will be charged to stockholder’s equity upon the completion of the Proposed Public Offering. Should the Proposed Public Offering prove to be unsuccessful, these deferred costs, as well as additional expenses to be incurred, will be charged to operations.	Offering Costs Associated with the Initial Public Offering Offering costs consisted of legal, accounting, underwriting fees and other costs incurred through the Initial Public Offering that were charged to stockholders’ equity upon the completion of the Initial Public Offering. The Company classifies deferred underwriting commissions as non-current
Class A Common Stock Subject to Possible Redemption		Class A Common Stock Subject to Possible Redemption The Company accounts for its Class A common stock subject to possible redemption in accordance with the guidance in ASC Topic 480 “Distinguishing Liabilities from Equity.” Class A common stock subject to mandatory redemption (if any) is classified as liability instruments and are measured at fair value. Conditionally redeemable Class A common stock (including Class A common stock that features redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control) are classified as temporary equity. At all other times, Class A common stock is classified as stockholders’ equity. As part of the Private Placement, the Company issued 602,500 shares of Class A common stock to the Sponsor (“Private Placement Shares”). These Private Placement Shares will not be transferable, assignable or salable until 30 days after the completion of our initial business combination, as such are considered non-redeemable Effective with the closing of the Initial Public Offering, the Company recognized the accretion from initial book value to redemption amount, which resulted in charges against additional paid-in
Income Taxes	Income Taxes The Company follows the asset and liability method of accounting for income taxes under FASB ASC 740, “Income Taxes.” Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. Deferred tax assets were deemed immaterial as of December 31, 2020. FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of December 31, 2020. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception. The provision for income taxes was deemed to be de minimis for the period from August 21, 2020 (inception) through December 31, 2020.	Income Taxes The Company follows the asset and liability method of accounting for income taxes under FASB ASC Topic 740, “Income Taxes” (“ASC 740”). Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. As of September 30, 2021, and December 31, 2020, the Company had deferred tax assets with a full valuation allowance against them. FASB ASC 740 prescribes a recognition threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination by taxing authorities. There were no unrecognized tax benefits as of September 30, 2021 or December 31, 2020. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense. No amounts were accrued for the payment of interest and penalties as of September 30, 2021 and December 31, 2020. The Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from its position. The Company is subject to income tax examinations by major taxing authorities since inception.
Net Loss Per Share	Net Loss Per Common Share The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” Net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period, excluding common stock subject to forfeiture. Weighted average shares at December 31, 2020 were reduced for the effect of an aggregate of 375,000 shares of Class B common stock that are subject to forfeiture by the Sponsor if the over-allotment option is not exercised in full or in part by the underwriters (see Note 6). At December 31, 2020, the Company did not have any dilutive securities and other contracts that could, potentially, be exercised or converted into shares of common stock and then share in the earnings of the Company. As a result, diluted loss per common share is the same as basic loss per common share for the period presented.	Net Income (Loss) Per Share of Common Stock The Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” The Company has two classes of shares, which are referred to as Class A common stock and Class B common stock. Income and losses are shared pro rata between the two classes of shares. Net income (loss) per common share is calculated by dividing the net income (loss) by the weighted average shares of common stock outstanding for the respective period. Accretion associated with the redeemable Class A common stock is excluded from earnings per share as the redemption value approximates fair value. The following table reflects presents a reconciliation of the numerator and denominator used to compute basic and diluted net income (loss) per share for each class of common stock: For the Three Months Ended For the Nine Months Ended Class A Class B Class A Class B Basic and diluted net loss per ordinary share: Numerator: Allocation of net loss $ (980,031 ) $ (237,886 ) $ (2,758,291 ) $ (793,731 ) Denominator: Basic and diluted weighted average ordinary shares outstanding 20,727,500 5,031,250 17,083,104 4,915,865 Basic and diluted net loss per ordinary share $ (0.05 ) $ (0.05 ) $ (0.16 ) $ (0.16 ) For the Period From Class A Class B Basic and diluted net loss per ordinary share: Numerator: Allocation of net loss $ — $ (1,032 ) Denominator: Basic and diluted weighted average ordinary shares outstanding — 4,375,000 Basic and diluted net loss per ordinary share $ — $ (0.00 )
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company’s management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying financial statements.	Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying unaudited condensed consolidated financial statements.

Basis of Presentation and Sum_2

Basis of Presentation and Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2021
Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share	Potentially dilutive securities not included in the calculation of diluted net loss per share because to do so would be anti-dilutive are as follows (in common stock equivalent shares): February 27, February 27, Nine (unaudited) Conversion of outstanding convertible preferred stock — — 13,923,356 Outstanding stock options — — 1,604,933 Restricted common stock subject to repurchase or forfeiture 6,859,000 6,261,500 4,554,285 Total 6,859,000 6,261,500 20,082,574
FS DEVELOPMENT CORP. II
Schedule of balance sheet	As of February 19, 2021 As Previously Adjustment As Restated Total assets $ 203,119,261 $ 203,119,261 Total liabilities $ 7,351,899 $ 7,351,899 Class A common stock subject to possible redemption 190,767,360 10,482,640 201,250,000 Preferred stock — — — Class A common stock 165 (105 ) 60 Class B common stock 503 — 503 Additional paid-in 5,051,492 (5,051,492 ) — Accumulated deficit (52,158 ) (5,430,983 ) (5,483,201 ) Total stockholders’ equity (deficit) $ 5,000,002 $ (10,482,640 ) $ (5,482,638 ) Total Liabilities, Class A Common Stock Subject to Possible Redemption and Stockholders’ Equity (Deficit) $ 203,119,261 $ — $ 203,119,261 As of March 31, 2021 As Previously Adjustment As Restated Total assets $ 202,959,356 $ 202,959,356 Total liabilities $ 7,284,061 $ 7,284,061 Class A common stock subject to possible redemption 190,675,290 10,574,710 201,250,000 Preferred stock — — — Class A common stock 166 (106 ) 60 Class B common stock 503 — 503 Additional paid-in 5,168,561 (5,168,561 ) — Accumulated deficit (169,225 ) (5,405,983 ) (5,575,268 ) Total stockholders’ equity (deficit) $ 5,000,005 $ (10,574,710 ) $ (5,574,705 ) Total Liabilities, Class A Common Stock Subject to Possible Redemption and Stockholders’ Equity (Deficit) $ 202,959,356 $ — $ 202,959,356 As of June 30, 2021 As Previously Adjustment As Restated Total assets $ 202,246,887 $ 202,246,887 Total liabilities $ 8,737,504 $ 8,737,504 Class A common stock subject to possible redemption 188,509,380 12,740,620 201,250,000 Preferred stock — — — Class A common stock 188 (128 ) 60 Class B common stock 503 — 503 Additional paid-in 7,334,449 (7,334,449 ) — Accumulated deficit (2,335,137 ) (5,405,983 ) (7,741,180 ) Total stockholders’ equity (deficit) $ 5,000,003 $ (12,740,620 ) $ (7,740,617 ) Total Liabilities, Class A Common Stock Subject to Possible Redemption and Stockholders’ Equity (Deficit) $ 202,246,887 $ — $ 202,246,887
Schedule of cash flows	Three Months Ended March 31, 2021 As Previously Adjustment As Restated Supplemental Disclosure of Noncash Financing Activities: Initial value of Class A common stock subject to possible redemption $ 190,767,360 $ (190,767,360 ) $ — Change in value of Class A common stock subject to possible redemption $ (92,070 ) $ 92,070 $ — Six Months Ended June 30, 2021 As Previously Adjustment As Restated Supplemental Disclosure of Noncash Financing Activities: Initial value of Class A common stock subject to possible redemption $ 190,767,360 $ (190,767,360 ) $ — Change in value of Class A common stock subject to possible redemption $ (2,257,980 ) $ 2,257,980 $ —
Schedule of statements of operations	Earnings Per Share As Previously Adjustment As Restated Three Months Ended March 31, 2021 Net loss $ (168,193 ) $ — $ (168,193 ) Weighted average shares outstanding – Class A common stock 20,727,500 (11,054,667 ) 9,672,833 Basic and diluted earnings per share – Class A common stock $ — $ (0.01 ) $ (0.01 ) Weighted average shares outstanding – Class B common stock 4,681,250 4,681,250 Basic and diluted earnings per share – Class B common stock $ (0.04 ) $ 0.03 $ (0.01 ) Earnings Per Share As Previously Adjustment As Restated Three Months Ended June 30, 2021 Net loss $ (2,165,912 ) $ — $ (2,165,912 ) Weighted average shares outstanding – Class A common stock 20,125,000 602,500 20,727,500 Basic and diluted earnings per share – Class A common stock $ — $ (0.08 ) $ (0.08 ) Weighted average shares outstanding – Class B common stock 5,633,750 5,031,250 Basic and diluted earnings per share – Class B common stock $ (0.38 ) $ 0.30 $ (0.08 ) Earnings Per Share As Previously Adjustment As Restated Six Months Ended June 30, 2021 Net loss $ (2,334,105 ) $ — $ (2,334,105 ) Weighted average shares outstanding – Class A common stock 20,125,000 (4,894,296 ) 15,230,704 Basic and diluted earnings per share – Class A common stock $ — $ (0.12 ) $ (0.12 ) Weighted average shares outstanding – Class B common stock 5,299,938 4,857,217 Basic and diluted earnings per share – Class B common stock $ (0.44 ) $ 0.32 $ (0.12 )
Schedule of basic and diluted net income (loss) per share	For the Three Months Ended For the Nine Months Ended Class A Class B Class A Class B Basic and diluted net loss per ordinary share: Numerator: Allocation of net loss $ (980,031 ) $ (237,886 ) $ (2,758,291 ) $ (793,731 ) Denominator: Basic and diluted weighted average ordinary shares outstanding 20,727,500 5,031,250 17,083,104 4,915,865 Basic and diluted net loss per ordinary share $ (0.05 ) $ (0.05 ) $ (0.16 ) $ (0.16 ) For the Period From Class A Class B Basic and diluted net loss per ordinary share: Numerator: Allocation of net loss $ — $ (1,032 ) Denominator: Basic and diluted weighted average ordinary shares outstanding — 4,375,000 Basic and diluted net loss per ordinary share $ — $ (0.00 )

Class A Common Stock Subject _2

Class A Common Stock Subject to Possible Redemption (Tables)	9 Months Ended
	Sep. 30, 2021
FS DEVELOPMENT CORP. II
Schedule of class A common stock subject to possible redemption	Gross proceeds from Initial Public Offering $ 201,250,000 Less: Offering costs allocated to Class A common stock subject to possible redemption (11,455,480 ) Plus: Accretion of carrying value to redemption value 11,455,480 Class A common stock subject to possible redemption $ 201,250,000

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	9 Months Ended
	Sep. 30, 2021
Stockholders' Equity Note [Abstract]
Schedule of convertible preferred stock	As of September 30, 2021 (unaudited), convertible preferred stock consisted of (in thousands, except share and per-share Shares Shares Per Share Liquidation Carrying Series A 9,771,425 9,771,414 $ 4.5541 $ 44,500 $ 44,323 Series A-1 2,818,034 2,818,034 $ 1.2420 3,500 9,638 Series A-2 605,850 605,850 $ 2.4841 1,505 2,302 Series A-3 728,058 728,058 $ 2.8981 2,110 2,869 Total 13,923,367 13,923,356 $ 51,615 $ 59,132
Schedule of restricted common stock awards	A summary of the restricted common stock awards is as follows: Number of Balance at February 27, 2020 (inception) — Issued shares 6,983,000 Forfeited shares (133,000 ) Balance at December 31, 2020 6,850,000 Issued shares (unaudited) 75,000 Vested shares (unaudited) (2,376,715 ) Balance at September 30, 2021 (unaudited) 4,548,285
Schedule of stock option activity for employee and nonemployee awards	Stock option activity for employee and nonemployee awards and related information is as follows: Number Weighted- Weighted- Weighted- Aggregate Outstanding at December 31, 2020 — — Granted (unaudited) 1,718,433 $ 5.63 $ 3.91 Exercised (unaudited) (1,000 ) $ 4.44 Canceled (unaudited) (112,500 ) $ 5.42 Outstanding and expected to vest at September 30, 2021 (unaudited) 1,604,933 $ 5.64 9.6 $ 3.92 $ 5,824 Vested and exercisable at September 30, 2021 (unaudited) 9,248 $ 6.02 9.8 $ 4.05 $ 30
Schedule of weighted-average assumptions used in the Black-Scholes option pricing model	The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the stock options granted in the nine months ended September 30, 2021 (unaudited) were as follows: Assumed risk-free interest rate 1.1 % Assumed volatility 80.8 % Expected option life (in years) 6.2 Expected dividend yield — %
Schedule of allocation of stock-based compensation expense	The allocation of stock-based compensation expense for the nine months ended September 30, 2021 (unaudited) was as follows (in thousands): Research and development $ 246 General and administrative 404 Total stock-based compensation $ 650
Schedule of common stock reserved for future issuance	Common stock reserved for future issuance consists of the following: December 31, September 30, (unaudited) Conversion of outstanding convertible preferred stock — 13,923,356 Outstanding stock options — 1,604,933 Shares available for issuance under the Plan 991,000 1,525,051 Total 991,000 17,053,340

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2021
Schedule of reconciliation of all liabilities measured at fair value	The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands): 2020 SAFEs issued in the 2020 period $ 7,115 Change in fair value during the 2020 period 7,693 Balance as of December 31, 2020 14,808 Conversion into shares of convertible preferred stock (unaudited) (14,808 ) Balance as of September 30, 2021 (unaudited) $ —
FS DEVELOPMENT CORP. II
Schedule of fair value hierarchy of the valuation techniques	Description Quoted Significant Significant Investments held in Trust Account – money market funds $ 201,262,131 $ — $ —

Income Taxes - (Tables)

Income Taxes - (Tables)	9 Months Ended
	Sep. 30, 2021
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation	A reconciliation of the Company’s income taxes to the amount computed by applying the statutory federal income tax rate to the pretax loss for the period February 27, 2020 (inception) to December 31, 2020 is summarized as follows (in thousands): Expected income tax benefit at statutory rates $ (2,731 ) Permanent items 35 Change in fair value of 2020 SAFEs 1,616 Research credits (32 ) Valuation allowance 1,112 $ —
Schedule of Deferred Tax Assets and Liabilities	As of December 31, 2020, significant components of the Company’s deferred income taxes are as follows (in thousands): Deferred tax assets: Net operating loss carryforward $ 1,078 Research credit carryforwards 31 Other, net 3 Total deferred tax assets 1,112 Less valuation allowance (1,112 ) Net deferred tax assets $ —

Description of Organization a_2

Description of Organization and Business Operations (Details) - USD ($)	Feb. 19, 2021	Aug. 26, 2020	Feb. 19, 2021	Dec. 31, 2020	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Aug. 20, 2020	Feb. 19, 2019
Description of Organization and Business Operations (Details) [Line Items]
Common stock par value (in Dollars per share)				$ 0.00001	$ 0.00001	$ 0.00001
Gross proceeds			$ 201,300,000
Net proceeds					$ 201,300,000
Aggregate cash proceeds					$ 100,000,000
Entity Incorporation, Date of Incorporation					Feb. 27, 2020
Accumulated deficit				$ (13,006,000)	$ (37,177,000)	$ (13,006,000)
Cash and cash equivalents				$ 3,410,000	26,384,000	3,410,000	$ 3,449,000
Proceeds from Issuance of Convertible Preferred Stock					44,500,000	$ 44,500,000
Working capital deficit					$ 1,800,000
FS DEVELOPMENT CORP. II
Description of Organization and Business Operations (Details) [Line Items]
Share price per share (in Dollars per share)					$ 10
Percentage of fair market value				80.00%	80.00%
Ownership percentage				50.00%	50.00%	50.00%
Public price per share (in Dollars per share)				$ 10	$ 10
Net tangible assets				$ 5,000,001	$ 5,000,001	$ 5,000,001
Percentage of restricted redeeming shares				20.00%	20.00%	20.00%
Share price (in Dollars per share)					$ 10
Business combination agreement, description				the residual assets remaining available for distribution (including Trust Account assets) will be only $10.00. In order to protect the amounts held in the Trust Account, the Sponsor has agreed to be liable to the Company if and to the extent any claims by a third party (except for the Company’s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a letter of intent, confidentiality or other similar agreement or business combination agreement (a “Target”), reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per Public Share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or Target that executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriters of the Proposed Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”).	In order to protect the amounts held in the Trust Account, the Sponsor agreed to be liable to the Company if and to the extent any claims by a third party (except for the Company’s independent registered public accounting firm) for services rendered or products sold to the Company, or a prospective target business with which the Company has entered into a letter of intent, confidentiality or other similar agreement or business combination agreement (a “Target”), reduce the amount of funds in the Trust Account to below the lesser of (i) $10.00 per Public Share and (ii) the actual amount per Public Share held in the Trust Account as of the date of the liquidation of the Trust Account, if less than $10.00 per Public Share due to reductions in the value of the trust assets, less taxes payable, provided that such liability will not apply to any claims by a third party or Target that executed a waiver of any and all rights to the monies held in the Trust Account (whether or not such waiver is enforceable) nor will it apply to any claims under the Company’s indemnity of the underwriter of the Initial Public Offering against certain liabilities, including liabilities under the Securities Act of 1933, as amended (the “Securities Act”)
Conditions to closing description					Under the Merger Agreement, the obligations of the parties to consummate the Merger are subject to the satisfaction or waiver of certain customary closing conditions of the respective parties, including, without limitation: (i) the approval and adoption of the Merger Agreement and transactions contemplated thereby by requisite vote of the Company’s stockholders (the “Company Stockholder Approval”) and Pardes’ stockholders (the “Pardes Stockholder Approval”); (ii) the receipt of consents or approvals from the applicable governmental, regulatory or administrative authorities; (iii) the aggregate cash proceeds from Company’s trust account, together with the proceeds from the Subscriptions (as defined below), equaling no less than $100,000,000 (after deducting any amounts paid to Company stockholders that exercise their redemption rights in connection with the Merger and net of the Company’s unpaid liabilities), (iv) (A) the representations and warranties of the Company, Pardes and Merger Sub contained in the Merger Agreement (other than each party’s respective Fundamental Representations, as defined in the Merger Agreement) being true and correct as of the date of the Merger Agreement and as of the Closing Date, except for any failure to be true and correct that would not have or reasonably be expected to have a Material Adverse Effect (as defined in the Merger Agreement) and (B) each party’s respective Fundamental Representations being true and correct as of the date of the Merger Agreement and as of the Closing Date, except for de minimis inaccuracies; (v) the absence of a Material Adverse Effect since the date of the Merger Agreement; (vi) the Company has not redeemed the Class A Common Stock of the Company in an amount that would cause the Company to have net tangible assets of less than $5,000,001; and (vii) the Company’s initial listing application with Nasdaq in connection with the Merger has been conditionallyapproved and, immediately following the effective time of the Merger, the Company has satisfied any applicable initial and continuing listing requirements of Nasdaq, and the Company has not received any notice of non-compliance therewith, and the shares of the Company’s Class A Common Stock has been approved for listing on Nasdaq.
Tax obligations					$ 149,000
Loan proceeds					200,000
Accumulated deficit				$ (1,032)	(8,959,097)	$ (1,032)
Cash and cash equivalents				$ 8,800	48,330	$ 8,800	$ 16,800
FS DEVELOPMENT CORP. II | Liquidity And Capital Resources [Member]
Description of Organization and Business Operations (Details) [Line Items]
Cash					$ 48,000
Business Acquisition [Member] | FS DEVELOPMENT CORP. II
Description of Organization and Business Operations (Details) [Line Items]
Company's obligation to redeemed, percentage				100.00%	100.00%	100.00%
Business combination, description				If the Company is unable to complete a Business Combination within 24 months from the closing of the Proposed Public Offering or during any extended period of time that the Company may have to consummate a Business Combination as a result of an amendment to the Certificate of Incorporation (the “Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish Public Stockholders’ rights as stockholders (including the right toreceive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the board of directors, liquidate and dissolve, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.	If the Company is unable to complete a Business Combination within 24 months from the closing of the Initial Public Offering, or February 19, 2023, or during any extended period of time that the Company may have toconsummate a Business Combination as a result of an amendment to the Certificate of Incorporation (the “Combination Period”), the Company will (i) cease all operations except for the purpose of winding up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its taxes (less up to $100,000 of interest to pay dissolution expenses), divided by the number of then outstanding Public Shares, which redemption will completely extinguish Public Stockholders’ rights as stockholders (including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such redemption, subject to the approval of the remaining stockholders and the board of directors, liquidate and dissolve, subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of other applicable law.
Initial Public Offering [Member] | FS DEVELOPMENT CORP. II
Description of Organization and Business Operations (Details) [Line Items]
Number of shares issued (in Shares)	20,125,000		20,125,000
Share price per share (in Dollars per share)	$ 10		$ 10
Gross proceeds			$ 201,300,000
Offering costs	$ 11,500,000		11,500,000
Deferred underwriting commission			$ 7,000,000
Payment to offering cost					$ 25,000
Accumulated deficit					$ 5,400,000
Over-Allotment Option [Member] | FS DEVELOPMENT CORP. II
Description of Organization and Business Operations (Details) [Line Items]
Number of shares issued (in Shares)	2,625,000		2,625,000	11,500,000		11,500,000
Sale of shares (in Shares)				430,000
Private Placement [Member] | FS DEVELOPMENT CORP. II
Description of Organization and Business Operations (Details) [Line Items]
Number of shares issued (in Shares)		400,000							602,500
Share price per share (in Dollars per share)	$ 10	$ 10	$ 10	$ 10		$ 10
Gross proceeds	$ 6,000,000	$ 4
Proposed Public Offering [Member] | FS DEVELOPMENT CORP. II
Description of Organization and Business Operations (Details) [Line Items]
Number of shares issued (in Shares)				10,000,000		10,000,000
Share price per share (in Dollars per share)				$ 10		$ 10
Sale of per share price (in Dollars per share)				$ 10		$ 10
Public Shares [Member] | FS DEVELOPMENT CORP. II
Description of Organization and Business Operations (Details) [Line Items]
Share price per share (in Dollars per share)	$ 10		10
Private Placement Shares [Member] | FS DEVELOPMENT CORP. II
Description of Organization and Business Operations (Details) [Line Items]
Share price per share (in Dollars per share)					$ 10
Gross proceeds					$ 6,000,000
Common Class A [Member] | FS DEVELOPMENT CORP. II
Description of Organization and Business Operations (Details) [Line Items]
Number of shares issued (in Shares)				10,000,000		10,000,000
Common stock par value (in Dollars per share)	$ 0.0001		$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Share price per share (in Dollars per share)				$ 10	$ 10	$ 10
Exchange shares (in Shares)					32,500,000
Sale of shares (in Shares)				400,000
Common Class A [Member] | Over-Allotment Option [Member] | FS DEVELOPMENT CORP. II
Description of Organization and Business Operations (Details) [Line Items]
Number of shares issued (in Shares)	2,625,000		2,625,000	1,500,000		1,500,000
Common Class A [Member] | Private Placement [Member] | FS DEVELOPMENT CORP. II
Description of Organization and Business Operations (Details) [Line Items]
Number of shares issued (in Shares)					602,500

Basis of Presentation and Sum_3

Basis of Presentation and Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended	4 Months Ended	9 Months Ended
	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2021
Basis of Presentation and Summary of Significant Accounting Policies (Details) [Line Items]
Accumulated deficit		$ (13,006,000)	$ (37,177,000)
Company issued shares (in Shares)		6,859,000	6,935,000
Capitalized deferred offering costs		$ 0
Threshold Percentage Of Tax Benefit To Be Realized Upon Ultimate Settlement With Tax Authority			50.00%
Other Asset [Member]
Basis of Presentation and Summary of Significant Accounting Policies (Details) [Line Items]
Deferred offering costs			$ 1,500,000
FS DEVELOPMENT CORP. II
Basis of Presentation and Summary of Significant Accounting Policies (Details) [Line Items]
Net Tangible Assets			5,000,001
Subject to possible redemption			10,500,000
Additional paid in capital		24,712
Accumulated deficit		(1,032)	(8,959,097)
Reclassification common stock (in Shares)	6,000,000
Federal deposit insurance corporation coverage limit			250,000
Federal depository insurance coverage		$ 250,000,000
Common stock subject to forfeiture		375,000
IPO [Member] | FS DEVELOPMENT CORP. II
Basis of Presentation and Summary of Significant Accounting Policies (Details) [Line Items]
Additional paid in capital			5,100,000
Accumulated deficit			$ 5,400,000
Class A Common Stock [Member] | FS DEVELOPMENT CORP. II
Basis of Presentation and Summary of Significant Accounting Policies (Details) [Line Items]
Reclassification common stock (in Shares)			1,048,264
Company issued shares (in Shares)		0	602,500
Common stock subject to possible redemption (in Shares)			20,125,000
Class A Common Stock [Member] | Private Placement [Member] | FS DEVELOPMENT CORP. II
Basis of Presentation and Summary of Significant Accounting Policies (Details) [Line Items]
Company issued shares (in Shares)			602,500

Basis of Presentation and Sum_4

Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of balance sheet - USD ($)	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Feb. 19, 2021	Dec. 31, 2020	Sep. 30, 2020	Aug. 20, 2020	Feb. 26, 2020
Condensed Balance Sheet Statements, Captions [Line Items]
Total assets	$ 28,581,000				$ 3,604,000
Total liabilities	5,971,000				16,610,000
Common stock
Additional paid-in capital	655,000
Total stockholders' equity (deficit)	(36,522,000)				(13,006,000)	$ (3,665,000)
FS DEVELOPMENT CORP. II
Condensed Balance Sheet Statements, Captions [Line Items]
Total assets	201,832,718				91,700
Total liabilities	9,541,252				67,732
Preferred stock
Common stock	60
Additional paid-in capital					24,497
Total stockholders' equity (deficit)	(8,958,534)	$ (7,740,617)	$ (5,574,705)		23,968	23,968	$ 25,000
Class A Common Stock [Member] | FS DEVELOPMENT CORP. II
Condensed Balance Sheet Statements, Captions [Line Items]
Total stockholders' equity (deficit)	60	60	60
Class B Common Stock [Member] | FS DEVELOPMENT CORP. II
Condensed Balance Sheet Statements, Captions [Line Items]
Total stockholders' equity (deficit)	$ 503	503	503		$ 503	$ 503	$ 503
As Previously Reported [Member] | FS DEVELOPMENT CORP. II
Condensed Balance Sheet Statements, Captions [Line Items]
Total assets		202,246,887	202,959,356	$ 203,119,261
Total liabilities		8,737,504	7,284,061	7,351,899
Class A common stock subject to possible redemption		188,509,380	190,675,290	190,767,360
Preferred stock
Additional paid-in capital			5,168,561	5,051,492
Accumulated deficit		(2,335,137)	(169,225)	(52,158)
Total stockholders' equity (deficit)		5,000,003	5,000,005	5,000,002
Total Liabilities, Class A Common Stock Subject to Possible Redemption and Stockholders' Equity (Deficit)		202,246,887	202,959,356	203,119,261
As Previously Reported [Member] | Class A Common Stock [Member] | FS DEVELOPMENT CORP. II
Condensed Balance Sheet Statements, Captions [Line Items]
Common stock		188	166	165
As Previously Reported [Member] | Class B Common Stock [Member] | FS DEVELOPMENT CORP. II
Condensed Balance Sheet Statements, Captions [Line Items]
Common stock		503	503	503
Additional paid-in capital		7,334,449
Adjustment [Member] | FS DEVELOPMENT CORP. II
Condensed Balance Sheet Statements, Captions [Line Items]
Class A common stock subject to possible redemption		12,740,620	10,574,710	10,482,640
Preferred stock
Additional paid-in capital			(5,168,561)	(5,051,492)
Accumulated deficit		(5,405,983)	(5,405,983)	(5,430,983)
Total stockholders' equity (deficit)		(12,740,620)	(10,574,710)	(10,482,640)
Total Liabilities, Class A Common Stock Subject to Possible Redemption and Stockholders' Equity (Deficit)
Adjustment [Member] | Class A Common Stock [Member] | FS DEVELOPMENT CORP. II
Condensed Balance Sheet Statements, Captions [Line Items]
Common stock		(128)	(106)	(105)
Adjustment [Member] | Class B Common Stock [Member] | FS DEVELOPMENT CORP. II
Condensed Balance Sheet Statements, Captions [Line Items]
Common stock
Additional paid-in capital		(7,334,449)
As Restated [Member] | FS DEVELOPMENT CORP. II
Condensed Balance Sheet Statements, Captions [Line Items]
Total assets		202,246,887	202,959,356	203,119,261
Total liabilities		8,737,504	7,284,061	7,351,899
Class A common stock subject to possible redemption		201,250,000	201,250,000	201,250,000
Preferred stock
Additional paid-in capital
Accumulated deficit		(7,741,180)	(5,575,268)	(5,483,201)
Total stockholders' equity (deficit)		(7,740,617)	(5,574,705)	(5,482,638)
Total Liabilities, Class A Common Stock Subject to Possible Redemption and Stockholders' Equity (Deficit)		202,246,887	202,959,356	203,119,261
As Restated [Member] | Class A Common Stock [Member] | FS DEVELOPMENT CORP. II
Condensed Balance Sheet Statements, Captions [Line Items]
Common stock		60	60	60
As Restated [Member] | Class B Common Stock [Member] | FS DEVELOPMENT CORP. II
Condensed Balance Sheet Statements, Captions [Line Items]
Common stock		503	$ 503	$ 503
Additional paid-in capital		$ 0

Basis of Presentation and Sum_5

Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of cash flows - FS DEVELOPMENT CORP. II - USD ($)	3 Months Ended	6 Months Ended
	Mar. 31, 2021	Jun. 30, 2021
As Previously Reported [Member]
Supplemental Disclosure of Noncash Financing Activities:
Initial value of Class A common stock subject to possible redemption	$ 190,767,360	$ 190,767,360
Change in value of Class A common stock subject to possible redemption	(92,070)	(2,257,980,000)
Adjustment [Member]
Supplemental Disclosure of Noncash Financing Activities:
Initial value of Class A common stock subject to possible redemption	(190,767,360)	(190,767,360)
Change in value of Class A common stock subject to possible redemption	92,070	2,257,980,000
As Restated [Member]
Supplemental Disclosure of Noncash Financing Activities:
Initial value of Class A common stock subject to possible redemption
Change in value of Class A common stock subject to possible redemption

Basis of Presentation and Sum_6

Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of statements of operations - USD ($)		1 Months Ended	3 Months Ended			4 Months Ended	6 Months Ended	7 Months Ended	9 Months Ended	10 Months Ended
		Sep. 30, 2020	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Jun. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Dec. 31, 2020
Condensed Income Statements, Captions [Line Items]
Net loss (in Dollars)								$ (3,665,000)	$ (24,171,000)	$ (13,006,000)
Weighted average shares outstanding (in Shares)									1,463,172
Basic and diluted earnings per share									$ (16.52)
FS DEVELOPMENT CORP. II
Condensed Income Statements, Captions [Line Items]
Net loss (in Dollars)		$ (1,032)	$ (1,217,917)			$ (1,032)			$ (3,552,022)
Weighted average shares outstanding (in Shares)	[1]					2,500,000
Basic and diluted earnings per share						$ 0
Class A Common Stock [Member] | FS DEVELOPMENT CORP. II
Condensed Income Statements, Captions [Line Items]
Weighted average shares outstanding (in Shares)			20,727,500						17,083,104
Basic and diluted earnings per share			$ (0.05)						$ (0.16)
Class B Common Stock [Member] | FS DEVELOPMENT CORP. II
Condensed Income Statements, Captions [Line Items]
Weighted average shares outstanding (in Shares)		4,375,000	5,031,250						4,915,865
Basic and diluted earnings per share		$ 0	$ (0.05)						$ (0.16)
As Previously Reported [Member] | FS DEVELOPMENT CORP. II
Condensed Income Statements, Captions [Line Items]
Net loss (in Dollars)				$ (2,165,912)	$ (168,193)		$ (2,334,105)
As Previously Reported [Member] | Class A Common Stock [Member] | FS DEVELOPMENT CORP. II
Condensed Income Statements, Captions [Line Items]
Weighted average shares outstanding (in Shares)				20,125,000	20,727,500		20,125,000
Basic and diluted earnings per share
As Previously Reported [Member] | Class B Common Stock [Member] | FS DEVELOPMENT CORP. II
Condensed Income Statements, Captions [Line Items]
Weighted average shares outstanding (in Shares)				5,633,750	4,681,250		5,299,938
Basic and diluted earnings per share				$ (0.38)	$ (0.04)		$ (0.44)
Adjustment [Member] | FS DEVELOPMENT CORP. II
Condensed Income Statements, Captions [Line Items]
Net loss (in Dollars)
Adjustment [Member] | Class A Common Stock [Member] | FS DEVELOPMENT CORP. II
Condensed Income Statements, Captions [Line Items]
Weighted average shares outstanding (in Shares)				602,500	(11,054,667)		(4,894,296)
Basic and diluted earnings per share				$ (0.08)	$ (0.01)		$ (0.12)
Adjustment [Member] | Class B Common Stock [Member] | FS DEVELOPMENT CORP. II
Condensed Income Statements, Captions [Line Items]
Basic and diluted earnings per share				$ 0.30	$ 0.03		$ 0.32
As Restated [Member] | FS DEVELOPMENT CORP. II
Condensed Income Statements, Captions [Line Items]
Net loss (in Dollars)				$ (2,165,912)	$ (168,193)		$ (2,334,105)
As Restated [Member] | Class A Common Stock [Member] | FS DEVELOPMENT CORP. II
Condensed Income Statements, Captions [Line Items]
Weighted average shares outstanding (in Shares)				20,727,500	9,672,833		15,230,704
Basic and diluted earnings per share				$ (0.08)	$ (0.01)		$ (0.12)
As Restated [Member] | Class B Common Stock [Member] | FS DEVELOPMENT CORP. II
Condensed Income Statements, Captions [Line Items]
Weighted average shares outstanding (in Shares)				5,031,250	4,681,250		4,857,217
Basic and diluted earnings per share				$ (0.08)	$ (0.01)		$ (0.12)
[1]	This number excludes an aggregate of up to 375,000 shares of Class B common stock subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters.

Basis of Presentation and Sum_7

Basis of Presentation and Summary of Significant Accounting Policies (Details) - Schedule of basic and diluted net income (loss) per share - USD ($)		1 Months Ended	3 Months Ended	4 Months Ended	9 Months Ended
		Sep. 30, 2020	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2021
Denominator:
Basic and diluted weighted average ordinary shares outstanding					1,463,172
Basic and diluted net loss per ordinary share					$ (16.52)
FS DEVELOPMENT CORP. II
Denominator:
Basic and diluted weighted average ordinary shares outstanding	[1]			2,500,000
Basic and diluted net loss per ordinary share				$ 0
Class A Common Stock [Member] | FS DEVELOPMENT CORP. II
Numerator:
Allocation of net loss			$ (980,031)		$ (2,758,291)
Denominator:
Basic and diluted weighted average ordinary shares outstanding			20,727,500		17,083,104
Basic and diluted net loss per ordinary share			$ (0.05)		$ (0.16)
Class B Common Stock [Member] | FS DEVELOPMENT CORP. II
Numerator:
Allocation of net loss		$ (1,032)	$ (237,886)		$ (793,731)
Denominator:
Basic and diluted weighted average ordinary shares outstanding		4,375,000	5,031,250		4,915,865
Basic and diluted net loss per ordinary share		$ 0	$ (0.05)		$ (0.16)
[1]	This number excludes an aggregate of up to 375,000 shares of Class B common stock subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters.

Summary of Significant Accounti

Summary of Significant Accounting Policies - Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share (Detail) - shares	7 Months Ended	9 Months Ended	10 Months Ended
	Sep. 30, 2020	Sep. 30, 2021	Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,261,500	20,082,574	6,859,000
Conversion Of Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		13,923,356
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount		1,604,933
Restricted Common Stock Subject To Repurchase Or Forfeiture [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	6,261,500	4,554,285	6,859,000

Initial Public Offering (Detail

Initial Public Offering (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended
	Feb. 19, 2021	Sep. 30, 2021	Dec. 31, 2020
Initial Public Offering (Details) [Line Items]
Gross proceeds	$ 201.3
FS DEVELOPMENT CORP. II
Initial Public Offering (Details) [Line Items]
Shares issued price per share (in Dollars per share)		$ 10
FS DEVELOPMENT CORP. II | Class A Common Stock
Initial Public Offering (Details) [Line Items]
Number of shares issued (in Shares)			10,000,000
Shares issued price per share (in Dollars per share)		$ 10	$ 10
Initial Public Offering [Member] | FS DEVELOPMENT CORP. II
Initial Public Offering (Details) [Line Items]
Number of shares issued (in Shares)	20,125,000
Shares issued price per share (in Dollars per share)	$ 10
Gross proceeds	$ 201.3
Offering costs	11.5
Deferred underwriting commission	$ 7
Over-Allotment Option [Member] | FS DEVELOPMENT CORP. II
Initial Public Offering (Details) [Line Items]
Number of shares issued (in Shares)	2,625,000		11,500,000
Over-Allotment Option [Member] | FS DEVELOPMENT CORP. II | Class A Common Stock
Initial Public Offering (Details) [Line Items]
Number of shares issued (in Shares)	2,625,000		1,500,000

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)		Feb. 19, 2021	Feb. 05, 2021	Jan. 22, 2021	Aug. 26, 2020	Aug. 26, 2020	Feb. 19, 2021	Sep. 30, 2020	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2021	Dec. 31, 2020	Feb. 19, 2019
Related Party Transactions (Details) [Line Items]
Common stock, par value (in Dollars per share)									$ 0.00001	$ 0.00001	$ 0.00001	$ 0.00001
Gross proceeds							$ 201,300,000
Two Of The Current Executive Officers As Consultants [Member] | Consulting Arrangements
Related Party Transactions (Details) [Line Items]
Related party transaction, Expenses from transactions with related party											$ 12,000
Two Of The Current Executive Officers As Consultants [Member] | Consulting Arrangements | Accounts Payable Current [Member]
Related Party Transactions (Details) [Line Items]
Accounts payable, Related parties, Current										$ 100,000		$ 100,000
Two Of The Current Executive Officers As Consultants [Member] | Consulting Arrangements | General and Administrative Expense
Related Party Transactions (Details) [Line Items]
Related party transaction, Amounts of transaction												100,000
A Former Member Of Scientific Advisory Board Who Has Became A Member Of Board Of Directors | Consulting Arrangements | Accounts Payable Current [Member]
Related Party Transactions (Details) [Line Items]
Accounts payable, Related parties, Current										$ 700		700
A Former Member Of Scientific Advisory Board Who Has Became A Member Of Board Of Directors | Consulting Arrangements | Research and Development Expense [Member]
Related Party Transactions (Details) [Line Items]
Related party transaction, Amounts of transaction												5,000
FS DEVELOPMENT CORP. II
Related Party Transactions (Details) [Line Items]
Founder shares transferred (in Shares)				30,000
Aggregate of founder shares transferred (in Shares)				90,000
Stock splits, description			the Company effected a 1:11⁄2 stock split of the Class B Common Stock and on February 16, 2021, the Company effected a 1:11/6 stock split of the Class B Common Stock, resulting in the Sponsor holding an aggregate of 4,941,250 Founder Shares and there being an aggregate of 5,031,250 Founder Shares outstanding. The Sponsor agreed to forfeit up to 656,250 Founder Shares to the extent that the over-allotment option was not exercised in full by the underwriter, so that the Founder Shares would represent 20.0% of the Company’s issued and outstanding shares of common stock after the Initial Public Offering (excluding the Private Placement Shares).
Subject to forfeiture (in Shares)		656,250
Share price per share (in Dollars per share)									$ 10		$ 10
Founder shares, description										(i) one year after the completion of the initial Business Combination and (ii) the date following the completion of the initial Business Combination on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the stockholders having the right to exchange their common stock for cash, securities or other property and the Sponsor has agreed not to transfer, assign or sell any of its Private Placement Shares until 30 days after the completion of the initial Business Combination. Notwithstanding the foregoing, if the closing price of the Class A common stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination, the Founder Shares will be released from the lockup.	(i) one year after the completion of the initial Business Combination and (ii) the date following the completion of the initial Business Combination on which the Company completes a liquidation, merger, capital stock exchange or other similar transaction that results in all of the stockholders having the right to exchange their common stock for cash, securities or other property and the Sponsor agreed not to transfer, assign or sell any of its Private Placement Shares until 30 days after the completion of the initial Business Combination. Notwithstanding the foregoing, if the closing price of the Class A Common Stock equals or exceeds $12.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 150 days after the initial Business Combination, the Founder Shares will be released from the lockup.
Costs and expenses, related party					$ 200,000	$ 200,000
Borrowings		$ 200,000					$ 200,000			$ 50,000		$ 50,000
Working capital loans										1,500,000	$ 1,500,000
Office space										$ 10,000	10,000
Administrative expenses								$ 0	$ 30,000		$ 80,000
FS DEVELOPMENT CORP. II | Business Acquisition [Member]
Related Party Transactions (Details) [Line Items]
Business Combination price per share (in Dollars per share)									$ 10	$ 10	$ 10	$ 10
FS DEVELOPMENT CORP. II | Private Placement [Member]
Related Party Transactions (Details) [Line Items]
Number of shares issued (in Shares)					400,000	400,000							602,500
Share price per share (in Dollars per share)		$ 10			$ 10	$ 10	$ 10			10		10
Gross proceeds		$ 6,000,000				$ 4
FS DEVELOPMENT CORP. II | Class A Common Stock [Member]
Related Party Transactions (Details) [Line Items]
Common stock, par value (in Dollars per share)		$ 0.0001					$ 0.0001		0.0001	$ 0.0001	0.0001	$ 0.0001
Number of shares issued (in Shares)										10,000,000		10,000,000
Share price per share (in Dollars per share)									$ 10	$ 10	$ 10	$ 10
Interest to purchase of common stock amount											$ 5,000,000
Interest to purchase of common stock amount aggregate											$ 10,000,000
FS DEVELOPMENT CORP. II | Class A Common Stock [Member] | Private Placement [Member]
Related Party Transactions (Details) [Line Items]
Number of shares issued (in Shares)									602,500		602,500
FS DEVELOPMENT CORP. II | Class B Common Stock [Member]
Related Party Transactions (Details) [Line Items]
Issuance of ordinary shares (in Shares)	[1]									2,875,000
Common stock, par value (in Dollars per share)									$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
FS DEVELOPMENT CORP. II | Class B Common Stock [Member] | Founder Shares [Member]
Related Party Transactions (Details) [Line Items]
Issuance of ordinary shares (in Shares)					2,875,000	2,875,000
Common stock, par value (in Dollars per share)					$ 0.0001	$ 0.0001
FS DEVELOPMENT CORP. II | Class B Common Stock [Member] | Founder Shares [Member]
Related Party Transactions (Details) [Line Items]
Sponsor paid					$ 25,000	$ 25,000
Common stock, par value (in Dollars per share)					$ 0.0001	$ 0.0001
[1]	This number includes up to 375,000 shares of Class B common stock subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters.

Commitments and Contingencies (

Commitments and Contingencies (Details) - FS DEVELOPMENT CORP. II - shares	4 Months Ended	9 Months Ended
	Dec. 31, 2020	Sep. 30, 2021
Additional purchase share		2,625,000
Underwriting agreement, description	The underwriters are entitled to an underwriting discount of $0.20 per share, or $2.0 million in the aggregate (or $2.3 million in the aggregate if the underwriters’ over-allotment option is exercised in full), payable upon the closing of the Proposed Public Offering. In addition, $0.35 per share, or $3.5 million in the aggregate (or approximately $4.0 million in the aggregate if the underwriters’ over-allotment option is exercised in full) will be payable to the underwriters for deferred underwriting commissions.	The underwriter was entitled to an underwriting discount of $0.20 per share, or approximately $4.0 million in the aggregate, paid upon the closing of the Initial Public Offering. In addition, $0.35 per share, or approximately $7.0 million in the aggregate will be payable to the underwriter for deferred underwriting commissions.

Class A Common Stock Subject _3

Class A Common Stock Subject to Possible Redemption (Details) - $ / shares	Sep. 30, 2021	Feb. 19, 2021	Jan. 18, 2021	Dec. 31, 2020
Class A Common Stock Subject to Possible Redemption [Line Items]
Common stock, shares authorized	25,187,755		10,000,000	10,000,000
Common stock, par value (in Dollars per share)	$ 0.00001			$ 0.00001
FS DEVELOPMENT CORP. II
Class A Common Stock Subject to Possible Redemption [Line Items]
Common stock, shares authorized				10,000,000
FS DEVELOPMENT CORP. II | Class A Common Stock [Member]
Class A Common Stock Subject to Possible Redemption [Line Items]
Common stock, shares authorized	100,000,000			100,000,000
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001		$ 0.0001
Common stock subject to possible redemption	20,125,000

Class A Common Stock Subject _4

Class A Common Stock Subject to Possible Redemption (Details) - Schedule of class A common stock subject to possible redemption reflected on the balance sheet is reconciled - FS DEVELOPMENT CORP. II	9 Months Ended
	Sep. 30, 2021USD ($)shares
Schedule of class A common stock subject to possible redemption reflected on the balance sheet is reconciled [Abstract]
Gross proceeds from Initial Public Offering | $	$ 201,250,000
Less
Offering costs allocated to Class A common stock subject to possible redemption | shares	(11,455,480)
Plus
Accretion of carrying value to redemption value | shares	11,455,480
Class A common stock subject to possible redemption | $	$ 201,250,000

Stockholders' Deficit (Details)

Stockholders' Deficit (Details) - Schedule of convertible preferred stock - USD ($) $ / shares in Units, $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Temporary Equity [Line Items]
Shares Authorized	13,923,367
Shares Issued	13,923,356
Shares Outstanding	13,923,356
Liquidation Preference	$ 51,615
Carrying Value	$ 59,132
Series A Redeemable Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Shares Authorized	9,771,425
Shares Issued	9,771,414
Shares Outstanding	9,771,414
Per Share Original Issue Price	$ 4.5541
Liquidation Preference	$ 44,500
Carrying Value	$ 44,323
Series A One Redeemable Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Shares Authorized	2,818,034
Shares Issued	2,818,034
Shares Outstanding	2,818,034
Per Share Original Issue Price	$ 1.2420
Liquidation Preference	$ 3,500
Carrying Value	$ 9,638
Series A Two Redeemable Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Shares Authorized	605,850
Shares Issued	605,850
Shares Outstanding	605,850
Per Share Original Issue Price	$ 2.4841
Liquidation Preference	$ 1,505
Carrying Value	$ 2,302
Series A Three Redeemable Convertible Preferred Stock [Member]
Temporary Equity [Line Items]
Shares Authorized	728,058
Shares Issued	728,058
Shares Outstanding	728,058
Per Share Original Issue Price	$ 2.8981
Liquidation Preference	$ 2,110
Carrying Value	$ 2,869

Stockholders' Deficit (Detail_2

Stockholders' Deficit (Details) - Schedule of restricted common stock awards - shares	9 Months Ended	10 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issued shares		9,000	6,983,000
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Beginning balance	6,850,000	0
Issued shares	75,000	6,983,000
Forfeited shares		(133,000)
Vested shares	(2,376,715)
Ending balance	4,548,285	6,850,000	6,850,000

Stockholders' Deficit (Detail_3

Stockholders' Deficit (Details) - Schedule of stock option activity for employee and nonemployee awards - Share-based Payment Arrangement [Member] - 2020 Equity Incentive Plan $ / shares in Units, $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number, Granted | shares	1,718,433
Number, Exercised | shares	1,000
Number, Canceled | shares	(112,500)
Number, Outstanding and expected to vest | shares	1,604,933
Number, Vested and exercisable | shares	9,248
Weighted- Average Exercise Price, Granted	$ 5.63
Weighted- Average Exercise Price, Exercised	4.44
Weighted- Average Exercise Price, Canceled	5.42
Weighted- Average Exercise Price, Outstanding and expected to vest	5.64
Weighted- Average Exercise Price, Vested and exercisable	$ 6.02
Weighted- Average Remaining Contractual Term, Outstanding and expected to vest	9 years 7 months 6 days
Weighted- Average Remaining Contractual Term, Vested and exercisable	9 years 9 months 18 days
Weighted- Average Grant Date, Granted	$ 3.91
Weighted- Average Grant Date, Outstanding and expected to vest	3.92
Weighted- Average Grant Date, Vested and exercisable	$ 4.05
Aggregate Intrinsic Value, Outstanding and expected to vest | $	$ 5,824
Aggregate Intrinsic Value, Vested and exercisable | $	$ 30

Stockholders' Deficit (Detail_4

Stockholders' Deficit (Details) - Schedule of weighted-average assumptions used in the Black-Scholes option pricing model - Share-based Payment Arrangement [Member] - 2020 Equity Incentive Plan	9 Months Ended
	Sep. 30, 2021
Schedule Of Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Assumed risk-free interest rate	1.10%
Assumed volatility	80.80%
Expected option life	6 years 2 months 12 days

Stockholders' Deficit (Detail_5

Stockholders' Deficit (Details) - Schedule of allocation of stock-based compensation expense - Share-based Payment Arrangement [Member] - 2020 Equity Incentive Plan $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 650
Research and Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	246
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 404

Stockholders' Deficit (Parenthe

Stockholders' Deficit (Parenthetical) (Details) - Schedule of allocation of stock-based compensation expense - 2020 Equity Incentive Plan $ in Millions	9 Months Ended
	Sep. 30, 2021USD ($)
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Employee service share based compensation nonvested awards total compensation costs not yet recognized stock options	$ 5.6
Share-based Payment Arrangement [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Employee service share based compensation non vested awards total compensation costs cost not yet recognized period for recognition	3 years 6 months

Stockholders' Deficit (Detail_6

Stockholders' Deficit (Details) - Schedule of common stock reserved for future issuance - shares	Sep. 30, 2021	Dec. 31, 2020
Schedule Of Common Stock Shares Reserved For Future Issuance [Line Items]
Common stock reserved for future issuance	17,053,340	991,000
Redeemable Convertible Preferred Stock [Member]
Schedule Of Common Stock Shares Reserved For Future Issuance [Line Items]
Common stock reserved for future issuance	13,923,356
Outstanding Stock Options [Member]
Schedule Of Common Stock Shares Reserved For Future Issuance [Line Items]
Common stock reserved for future issuance	1,604,933
Shares Available For Issuance Under The Plan [Member]
Schedule Of Common Stock Shares Reserved For Future Issuance [Line Items]
Common stock reserved for future issuance	1,525,051	991,000

Stockholders' Deficit (Detail_7

Stockholders' Deficit (Details) - USD ($) $ / shares in Units, $ in Millions		1 Months Ended		3 Months Ended	4 Months Ended	9 Months Ended	10 Months Ended	12 Months Ended
		Jan. 31, 2021	Sep. 30, 2020	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2020	Feb. 19, 2021	Jan. 19, 2021	Jan. 18, 2021	Aug. 26, 2020	Feb. 26, 2020
Stockholders' Equity (Details) [Line Items]
Common stock, shares authorized				25,187,755	10,000,000	25,187,755	10,000,000	10,000,000			10,000,000
Common stock, par value (in Dollars per share)				$ 0.00001	$ 0.00001	$ 0.00001	$ 0.00001	$ 0.00001
Weighted average shares outstanding, basic and diluted (in Shares)						1,463,172
Common Stock, Shares, Outstanding				2,380,715	0	2,380,715	0	0
Common stock, shares issued				6,935,000	6,859,000	6,935,000	6,859,000	6,859,000
Temporary equity shares authorized				13,923,367		13,923,367
Proceeds from redeemable convertible preferred stock		$ 44.5
Stock issued during the period restricted stock award gross							9,000	6,983,000
Common stock reserved for future issuance				17,053,340	991,000	17,053,340	991,000	991,000
Restricted Stock [Member]
Stockholders' Equity (Details) [Line Items]
Stock issued during the period restricted stock award gross						75,000	6,983,000
Share based compensation by share based award vesting percentage								25.00%
Restricted stock shares outstanding non vested				4,548,285	6,850,000	4,548,285	6,850,000	6,850,000					0
Restricted Stock [Member] | Portion at Fair Value Measurement [Member]
Stockholders' Equity (Details) [Line Items]
Restricted stock shares outstanding non vested				6,000		6,000
Restricted Stock [Member] | One Year From The Vesting Commencement Date [Member]
Stockholders' Equity (Details) [Line Items]
Share based compensation by share based award vesting percentage								25.00%
Restricted Stock [Member] | Thirty Six Moths After Completion Of One Year From The Vesting Commencement Date [Member]
Stockholders' Equity (Details) [Line Items]
Share based compensation by share based award vesting term								36 months
Share-based Payment Arrangement [Member] | 2020 Equity Incentive Plan
Stockholders' Equity (Details) [Line Items]
Common stock reserved for future issuance					991,000		991,000	991,000
Share based compensation by share based award number of shares authorized for issuance				3,139,984	1,000,000	3,139,984	1,000,000	1,000,000
Share based compensation by share based award number of additional shares authorized for issuance						2,139,984
Share based compensation by share based award number of shares available for grant				1,525,051		1,525,051
Condition For Conversion Of Redeemable Preferred Stock Into Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Offer for sale and sale of common stock premoney valuation				$ 200		$ 200
Estimated net proceeds from the offer for sale and sale of common stock						$ 50
Amended And Restated Articles Of Incorporation [Member]
Stockholders' Equity (Details) [Line Items]
Common stock, shares authorized										25,187,755
Series A Redeemable Convertible Preferred Stock [Member]
Stockholders' Equity (Details) [Line Items]
Temporary equity shares authorized				9,771,425		9,771,425
Series A One Redeemable Convertible Preferred Stock [Member]
Stockholders' Equity (Details) [Line Items]
Temporary equity shares authorized				2,818,034		2,818,034
Series A Two Redeemable Convertible Preferred Stock [Member]
Stockholders' Equity (Details) [Line Items]
Temporary equity shares authorized				605,850		605,850
Series A Three Redeemable Convertible Preferred Stock [Member]
Stockholders' Equity (Details) [Line Items]
Temporary equity shares authorized				728,058		728,058
Redeemable Convertible Preferred Stock [Member] | Amended And Restated Articles Of Incorporation [Member]
Stockholders' Equity (Details) [Line Items]
Temporary equity shares authorized										13,923,367
Redeemable Convertible Preferred Stock [Member] | Series A Redeemable Convertible Preferred Stock [Member]
Stockholders' Equity (Details) [Line Items]
Temporary equity stock shares issued during the period shares		9,771,414
Temporary equity dividend rate						8.00%
Dividend payable amount per share				$ 0		$ 0
Redeemable Convertible Preferred Stock [Member] | Series A Redeemable Convertible Preferred Stock [Member] | Amended And Restated Articles Of Incorporation [Member]
Stockholders' Equity (Details) [Line Items]
Temporary equity shares authorized										9,771,425
Redeemable Convertible Preferred Stock [Member] | Series A One Redeemable Convertible Preferred Stock [Member]
Stockholders' Equity (Details) [Line Items]
Temporary equity dividend rate						8.00%
Dividend payable amount per share				0		$ 0
Redeemable Convertible Preferred Stock [Member] | Series A One Redeemable Convertible Preferred Stock [Member] | Amended And Restated Articles Of Incorporation [Member]
Stockholders' Equity (Details) [Line Items]
Temporary equity shares authorized										2,818,034
Redeemable Convertible Preferred Stock [Member] | Series A Two Redeemable Convertible Preferred Stock [Member]
Stockholders' Equity (Details) [Line Items]
Temporary equity dividend rate						8.00%
Dividend payable amount per share				0		$ 0
Redeemable Convertible Preferred Stock [Member] | Series A Two Redeemable Convertible Preferred Stock [Member] | Amended And Restated Articles Of Incorporation [Member]
Stockholders' Equity (Details) [Line Items]
Temporary equity shares authorized										605,850
Redeemable Convertible Preferred Stock [Member] | Series A Three Redeemable Convertible Preferred Stock [Member]
Stockholders' Equity (Details) [Line Items]
Temporary equity dividend rate						8.00%
Dividend payable amount per share				$ 0		$ 0
Redeemable Convertible Preferred Stock [Member] | Series A Three Redeemable Convertible Preferred Stock [Member] | Amended And Restated Articles Of Incorporation [Member]
Stockholders' Equity (Details) [Line Items]
Temporary equity shares authorized										728,058
Redeemable Convertible Preferred Stock [Member] | Series A One A Two And A Three Redeemable Convertible Preferred Stock [Member] | Settlement Of Simple Agreement For Future Equity Notes [Member]
Stockholders' Equity (Details) [Line Items]
Temporary equity stock shares issued during the period shares		4,151,942
FS DEVELOPMENT CORP. II
Stockholders' Equity (Details) [Line Items]
Preferred stock, shares authorized				1,000,000	1,000,000	1,000,000	1,000,000	1,000,000
Preferred stock, par value (in Dollars per share)				$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Common stock, shares authorized					10,000,000		10,000,000	10,000,000
Shares subject to possible redemption				20,125,000		20,125,000
Weighted average shares outstanding, basic and diluted (in Shares)	[1]				2,500,000
Shareholders ownership, percentage				50.00%	50.00%	50.00%	50.00%	50.00%
FS DEVELOPMENT CORP. II | Founder Shares [Member]
Stockholders' Equity (Details) [Line Items]
Shareholders ownership, percentage				20.00%	20.00%	20.00%	20.00%	20.00%
FS DEVELOPMENT CORP. II | Class A Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Common stock, shares authorized				100,000,000	100,000,000	100,000,000	100,000,000	100,000,000
Common stock, par value (in Dollars per share)				$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Shares subject to possible redemption				20,125,000	0	20,125,000	0	0
Weighted average shares outstanding, basic and diluted (in Shares)				20,727,500		17,083,104
Common Stock, Shares, Outstanding				602,500	0	602,500	0	0
Common stock, shares issued				602,500	0	602,500	0	0
FS DEVELOPMENT CORP. II | Class B Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Common stock, shares authorized				10,000,000	10,000,000	10,000,000	10,000,000	10,000,000
Common stock, par value (in Dollars per share)				$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001	$ 0.0001
Weighted average shares outstanding, basic and diluted (in Shares)			4,375,000	5,031,250		4,915,865
Common Stock, Shares, Outstanding				5,031,250	5,031,250	5,031,250	5,031,250	5,031,250
Common stock, shares issued				5,031,250	5,031,250	5,031,250	5,031,250	5,031,250				2,875,000
FS DEVELOPMENT CORP. II | Class B Common Stock [Member] | Founder Shares [Member]
Stockholders' Equity (Details) [Line Items]
Common stock, par value (in Dollars per share)												$ 0.0001
[1]	This number excludes an aggregate of up to 375,000 shares of Class B common stock subject to forfeiture if the over-allotment option is not exercised in full or in part by the underwriters.

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Schedule of fair value hierarchy of the valuation techniques - FS DEVELOPMENT CORP. II	Sep. 30, 2021USD ($)
Quoted Prices in Active Markets (Level 1) [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Marketable securities held in Trust Account	$ 201,262,131
Significant Other Observable Inputs (Level 2) [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Marketable securities held in Trust Account
Significant Other Unobservable Inputs (Level 3) [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Marketable securities held in Trust Account

Fair Value Measurements (Deta_2

Fair Value Measurements (Details) - Schedule of reconciliation of all liabilities measured at fair value - 2020 Simple Agreements For Future Equity [Member] - Simple Agreements For Future Equity [Member] - Level 3 [Member] $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
2020 SAFEs issued in the 2020 period	$ 7,115
Change in fair value during the 2020 period	7,693
Beginning balance	14,808
Ending balance
Convertible Preferred Stock [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Conversion into shares of convertible preferred stock	$ (14,808)

Fair Value Measurements (Deta_3

Fair Value Measurements (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Financial Assets [Member] | Fair Value, Recurring [Member]
Fair Value Disclosures [Line Items]
Assets, fair value disclosure	$ 0	$ 0

Simple Agreements for Future _2

Simple Agreements for Future Equity (Details) - USD ($) $ / shares in Units, $ in Thousands	Jan. 19, 2021	Sep. 30, 2020	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2020	Sep. 30, 2021
Simple Agreements For Future Equity [Line Items]
Proceeds from issuance of SAFE agreements			$ 5,005	$ 7,100	$ 6,965
Number of simple agreement for future equity shares issued				4,151,942
Simple agreements for future equity (SAFE)				$ 14,808	14,808
Change in fair value of SAFE liability			$ 885		7,693
2020 SAFEs [Member]
Simple Agreements For Future Equity [Line Items]
Proceeds from issuance of SAFE agreements		$ 5,000
Fair value simple agreements for future equity	$ 14,800			14,800	14,800	$ 5,900
Simple agreements for future equity (SAFE)				14,800	$ 14,800
2020 SAFEs [Member] | Series A-1 preferred stock [Member]
Simple Agreements For Future Equity [Line Items]
Number of shares converted	2,818,034
Conversion price	$ 1.2420
2020 SAFEs [Member] | Series A-2 preferred stock [Member]
Simple Agreements For Future Equity [Line Items]
Number of shares converted	605,850
Conversion price	$ 2.4841
2020 SAFEs [Member] | Series A-3 preferred stock [Member]
Simple Agreements For Future Equity [Line Items]
Number of shares converted	728,058
Conversion price	$ 2.8981
2020 SAFEs [Member] | Other Expense [Member]
Simple Agreements For Future Equity [Line Items]
Change in fair value of SAFE liability		$ 900		$ 7,700

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of effective income tax rate reconciliation - USD ($) $ in Thousands	7 Months Ended	9 Months Ended	10 Months Ended
	Sep. 30, 2020	Sep. 30, 2021	Dec. 31, 2020
Expected income tax benefit at statutory rates			$ (2,731)
Permanent items			35
Change in fair value of 2020 SAFEs			1,616
Research credits			(32)
Valuation allowance			1,112
Income Tax Expense	$ 0	$ 0	$ 0

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of deferred tax assets and liabilities $ in Thousands	Dec. 31, 2020USD ($)
Deferred tax assets:
Net operating loss carryforward	$ 1,078
Research credit carryforwards	31
Other, net	3
Total deferred tax assets	1,112
Less valuation allowance	(1,112)
Net deferred tax assets	$ 0

Income Taxes (Details)

Income Taxes (Details) - USD ($)	Dec. 31, 2020	Sep. 30, 2020	Sep. 30, 2021	Dec. 31, 2020
Income tax expense benefit		$ 0	$ 0	$ 0
Deferred tax assets, Valuation allowance	$ 1,112,000			$ 1,112,000
Percentage of Cumulative change In Ownership Within A Three Year Testing Period Determining Limitation On Use Of Tax Attribute Carry forwards	50.00%			50.00%
Unrecognized tax benefits that would impact effective tax rate	$ 0			$ 0
Unrecognized tax benefits, Income tax penalties and interest accrued	0			0
Unrecognized tax benefits, Income tax penalties and interest expense				0
Balance Related To Federal And State Tax Credits And State NOLs
Unrecognized tax benefits	500,000			500,000
Domestic Country
Operating loss carryforwards	$ 5,100,000			5,100,000
Operating loss carryforwards, term	indefinitely
State and Local Jurisdiction
Operating loss carryforwards	$ 5,100,000			5,100,000
Operating loss carryforwards, expiration year	2040 years
Tax Credit Carry forward Term	indefinitely
Domestic Country And State And Local Jurisdiction
Tax credit carryforward, Amount	$ 52,000			$ 52,000

401(k) Plan - Additional Inform

401(k) Plan - Additional Information (Details) - USD ($)	9 Months Ended	10 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Four Hundred And One K Plan
Defined contribution plan, Employer discretionary contribution amount	$ 0	$ 0

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)	Nov. 10, 2021	Nov. 07, 2021	Jan. 15, 2021	Jan. 22, 2021	Sep. 30, 2021
Subsequent Event [Line Items]
Additional borrowing amount				$ 150,000
Convertible Note Purchase Agreement | Unsecured Convertible Promissory Term Notes Convertible Notes
Subsequent Event [Line Items]
Debt instrument, Interest rate during period	4.00%
Subsequent Event [Member]
Subsequent Event [Line Items]
Aggregate of founder shares					90,000
Outstanding amount				$ 200,000
Subsequent Event [Member] | Convertible Note Purchase Agreement | Unsecured Convertible Promissory Term Notes Convertible Notes
Subsequent Event [Line Items]
Maximum amount of convertible notes issued	$ 25,000,000
Notes issued	$ 10,000,000
Debt instrument, Maturity date	Oct. 31, 2022
Debt instrument, Payment terms	will be due and payable at the earlier of the closing under the Merger Agreement, the closing of a “corporate transaction” and at any time on or after the maturity date at Pardes’ election or upon demand of a purchaser.
Debt instrument, Convertible, Discounted price percentage applicable on conversion			15.00%
Convertible notes purchased			$ 10,000,000
Subsequent Event [Member] | Merger Of FS Development | Merger Agreement
Subsequent Event [Line Items]
Common stock, Value, Subscriptions		$ 75,000,000
Proceeds from merger transactions, Gross		276,000,000
Stock redeemed or called during period, Value		$ 0
Subsequent Event [Member] | Sponsor [Member]
Subsequent Event [Line Items]
Aggregate of founder shares				30,000